@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	1
@NP	Olfactory ensheathing cells	1
@NP	OECs	30
@NP	neurocan in injured spinal cord	44
@NP	neurocan	44
@NP	injured spinal cord	56
@NP	matrix metalloproteinase-2	89
@NP	a rat contusion model Yui , Sho	119
@NP	a rat contusion model	119
@NP	Yui , Sho	142
@NP	Fujita , Naoki	152
@NP	Fujita	152
@NP	Naoki	160
@NP	Chung , Cheng-Shu	167
@NP	Chung	167
@NP	Cheng-Shu	174
@NP	Morita , Maresuke	185
@NP	Morita	185
@NP	Maresuke	193
@NP	Nishimura , Ryohei Abstract The mechanism	203
@NP	Nishimura , Ryohei Abstract The	203
@NP	mechanism	235
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	254
@NP	olfactory ensheathing cells	254
@NP	OECs	283
@NP	functional recovery	322
@NP	transplantation	348
@NP	spinal cord injury -LRB- SCI -RRB-	369
@NP	spinal cord injury	369
@NP	SCI	389
@NP	the relevance of matrix metalloproteinases -LRB- MMPs -RRB-	430
@NP	the relevance	430
@NP	matrix metalloproteinases -LRB- MMPs -RRB-	447
@NP	matrix metalloproteinases	447
@NP	MMPs	474
@NP	We	500
@NP	the expression of MMPs	513
@NP	the expression	513
@NP	MMPs	531
@NP	OECs	539
@NP	the MMP secretion	557
@NP	OECs transplanted in injured spinal cord in vivo using a rat SCI model	578
@NP	OECs	578
@NP	injured spinal cord in vivo	599
@NP	injured spinal cord	599
@NP	vivo	622
@NP	a rat SCI model	633
@NP	We	650
@NP	the degradation	668
@NP	neurocan , which is one of the axon-inhibitory chondroitin sulfate proteoglycans	687
@NP	neurocan	687
@NP	one of the axon-inhibitory chondroitin sulfate proteoglycans	706
@NP	one	706
@NP	the axon-inhibitory chondroitin sulfate proteoglycans	713
@NP	SCI model rats	774
@NP	The	790
@NP	results	803
@NP	MMP-2	823
@NP	the dominant MMP expressed by OECs	833
@NP	the dominant MMP	833
@NP	OECs	863
@NP	The in vivo	869
@NP	The	869
@NP	vivo	876
@NP	transplanted OECs	903
@NP	MMP-2 in injured spinal cord	930
@NP	MMP-2	930
@NP	injured spinal cord	939
@NP	the expression of neurocan	968
@NP	the expression	968
@NP	neurocan	986
@NP	the transplantation of OECs	1026
@NP	the transplantation	1026
@NP	OECs	1049
@NP	These results	1055
@NP	OECs	1082
@NP	injured spinal cord degraded neurocan by secreting MMP-2	1105
@NP	injured spinal cord	1105
@NP	neurocan	1134
@NP	MMP-2	1156
@NP	Introduction Severe spinal cord injury -LRB- SCI -RRB-	1164
@NP	Introduction Severe spinal cord injury	1164
@NP	SCI	1204
@NP	traffic accidents or intervertebral disc diseases	1216
@NP	traffic accidents	1216
@NP	intervertebral disc diseases	1237
@NP	dogs9 ,11,15	1290
@NP	Patients with severe SCI	1304
@NP	Patients	1304
@NP	severe SCI	1318
@NP	irreversible quadriplegia or paraplegia and incontinence	1341
@NP	various clinical trials for SCI patients	1408
@NP	various clinical trials	1408
@NP	SCI patients	1436
@NP	a definitive treatment	1470
@NP	Cell transplantation therapy	1519
@NP	promising results	1584
@NP	Many types of cells	1623
@NP	Many types	1623
@NP	cells	1637
@NP	these studies	1664
@NP	embryonic stem cells , mesenchymal stem cells , neural stem and progenitor cells	1689
@NP	embryonic stem cells	1689
@NP	mesenchymal stem cells	1711
@NP	neural stem	1735
@NP	progenitor cells	1751
@NP	pluripotent stem cells6	1781
@NP	,23	1804
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	1812
@NP	Olfactory ensheathing cells	1812
@NP	OECs	1841
@NP	a promising candidate for cell transplantation therapy in SCI	1870
@NP	a promising candidate	1870
@NP	cell transplantation therapy in SCI	1896
@NP	cell transplantation therapy	1896
@NP	SCI	1928
@NP	OECs	1933
@NP	specific glial cells in the olfactory system	1942
@NP	specific glial cells	1942
@NP	the olfactory system	1966
@NP	they	1992
@NP	the notable ability to support axonal regeneration	2002
@NP	axonal regeneration	2033
@NP	A number of studies	2054
@NP	A number	2054
@NP	studies	2066
@NP	functional recovery	2088
@NP	OEC transplantation in SCI models2 ,7,13,17,19,25,27,28	2126
@NP	OEC transplantation	2126
@NP	SCI models2 ,7,13,17,19,25,27,28	2149
@NP	most	2192
@NP	these studies centered on the evaluation of functional recovery	2200
@NP	these studies	2200
@NP	the evaluation of functional recovery	2226
@NP	the evaluation	2226
@NP	functional recovery	2244
@NP	the mechanisms	2269
@NP	the functional recovery achieved with OEC transplantation	2295
@NP	the functional recovery	2295
@NP	OEC transplantation	2333
@NP	detail	2383
@NP	several mechanisms	2400
@NP	axonal regeneration by secreting neurotrophic factor4 -RRB-	2449
@NP	axonal regeneration	2449
@NP	neurotrophic factor4	2482
@NP	neurotrophic	2482
@NP	factor4	2495
@NP	remyelination of demyelinated axons2 ,7,18,19 -RRB-	2505
@NP	remyelination	2505
@NP	axons2 ,7,18,19	2535
@NP	axons2	2535
@NP	,7,18,19	2541
@NP	the protection of axons	2556
@NP	the protection	2556
@NP	axons	2574
@NP	that	2580
@NP	injury27	2594
@NP	no research	2605
@NP	a definite answer	2631
@NP	this question	2652
@NP	The irreversibility of SCI	2667
@NP	The irreversibility	2667
@NP	SCI	2690
@NP	chondroitin sulfate proteoglycans	2725
@NP	CSPGs	2760
@NP	these	2768
@NP	functional recovery from SCI	2782
@NP	functional recovery	2782
@NP	SCI	2807
@NP	axonal regeneration	2825
@NP	the injured spinal cord3 ,16,29	2848
@NP	the injured spinal cord3	2848
@NP	,16,29	2872
@NP	CSPGs	2881
@NP	several species	2895
@NP	an inhibitory effect on axonal regeneration	2916
@NP	an inhibitory effect	2916
@NP	axonal regeneration	2940
@NP	brevican , versican , neurocan , NG2 , and phosphacan8 ,12,20 -RRB-	2982
@NP	brevican , versican , neurocan , NG2 ,	2982
@NP	phosphacan8 ,12,20	3021
@NP	these five species	3044
@NP	neurocan	3064
@NP	the major inhibitory CSPG in SCI1	3102
@NP	the major inhibitory CSPG	3102
@NP	SCI1	3131
@NP	The degradation of CSPGs , especially neurocan ,	3138
@NP	The degradation	3138
@NP	CSPGs	3157
@NP	functional recovery	3194
@NP	rodent SCI models3	3217
@NP	,30	3235
@NP	The relevance of OECs and the degradation of CSPGs	3241
@NP	The relevance	3241
@NP	OECs and the degradation of CSPGs	3258
@NP	OECs	3258
@NP	the degradation of CSPGs	3267
@NP	the degradation	3267
@NP	CSPGs	3286
@NP	2006	3309
@NP	by Pastrana et al. 26	3314
@NP	Pastrana	3317
@NP	et al. 26	3326
@NP	et al.	3326
@NP	26	3332
@NP	They	3337
@NP	the mRNA expressions of matrix metalloproteinase-2 -LRB- MMP-2 -RRB-	3355
@NP	the mRNA expressions	3355
@NP	matrix metalloproteinase-2 -LRB- MMP-2 -RRB-	3379
@NP	matrix metalloproteinase-2	3379
@NP	MMP-2	3407
@NP	-9	3418
@NP	OECs	3433
@NP	they	3443
@NP	MMP-2	3460
@NP	the axonal regeneration of retinal neurons in vitro26 -RRB-	3475
@NP	the axonal regeneration	3475
@NP	retinal neurons	3502
@NP	vitro26	3521
@NP	MMPs	3531
@NP	a family of endopeptidases that contain Zn2 ＋ in the catalytic domain	3540
@NP	a family	3540
@NP	endopeptidases that contain Zn2 ＋ in the catalytic domain	3552
@NP	endopeptidases	3552
@NP	Zn2 ＋ in the catalytic domain	3580
@NP	Zn2 ＋	3580
@NP	the catalytic domain	3588
@NP	their main role in a living organism	3610
@NP	their main role	3610
@NP	a living organism	3629
@NP	the modulation of the extracellular matrix -LRB- ECM -RRB- 22	3650
@NP	the modulation of the extracellular matrix -LRB- ECM -RRB-	3650
@NP	the modulation	3650
@NP	the extracellular matrix -LRB- ECM -RRB-	3668
@NP	the extracellular matrix	3668
@NP	ECM	3694
@NP	22	3698
@NP	Several MMPs , including MMP-2 and -3 ,	3703
@NP	Several MMPs	3703
@NP	MMP-2 and -3	3727
@NP	MMP-2	3727
@NP	-3	3737
@NP	the ability to degrade CSPGs , which are a type of ECM21	3768
@NP	CSPGs , which are a type of ECM21	3791
@NP	CSPGs	3791
@NP	a type of ECM21	3808
@NP	a type	3808
@NP	ECM21	3818
@NP	Gueye et al.	3826
@NP	Gueye	3826
@NP	et al.	3832
@NP	a detailed report of MMP expression in OECs10 -RRB-	3849
@NP	a detailed report	3849
@NP	MMP expression	3870
@NP	OECs10	3888
@NP	the expression of MMP-3	3901
@NP	the expression	3901
@NP	MMP-3	3919
@NP	all five species of CSPGs that inhibit axonal regeneration	3958
@NP	all five species	3958
@NP	CSPGs that inhibit axonal regeneration	3978
@NP	CSPGs	3978
@NP	axonal regeneration	3997
@NP	OECs	4046
@NP	our knowledge	4055
@NP	the relevance	4079
@NP	MMP expression in OECs	4096
@NP	MMP expression	4096
@NP	OECs	4114
@NP	the degradation of CSPGs , especially neurocan , in injured spinal cord	4123
@NP	the degradation of CSPGs	4123
@NP	the degradation	4123
@NP	CSPGs	4142
@NP	injured spinal cord	4173
@NP	detail	4223
@NP	this study	4234
@NP	we	4246
@NP	the mRNA expression and protein secretion of MMP-2 , -3 and -9	4259
@NP	the mRNA expression and protein secretion	4259
@NP	MMP-2 , -3 and -9	4304
@NP	MMP-2	4304
@NP	-3	4311
@NP	-9	4318
@NP	rat OECs	4333
@NP	we	4347
@NP	MMPs	4367
@NP	OECs	4409
@NP	We	4415
@NP	the degradation of neurocan	4433
@NP	the degradation	4433
@NP	neurocan	4452
@NP	the MMPs	4464
@NP	the dominant MMPs	4487
@NP	OECs	4517
@NP	OEC transplantation	4529
@NP	SCI model animals	4554
@NP	Materials and Methods Animals	4574
@NP	Materials	4574
@NP	Methods Animals	4588
@NP	Thirty-six 8-week-old female Sprague	4605
@NP	Dawley	4643
@NP	SD	4651
@NP	rats	4655
@NP	culture OECs	4673
@NP	six 10-week-old female SD rats	4687
@NP	the induced SCI model	4732
@NP	one 13-week-old SD rat	4759
@NP	spinal cord tissue for hematoxylin-eosin -LRB- HE -RRB-	4809
@NP	spinal cord tissue	4809
@NP	hematoxylin-eosin -LRB- HE -RRB-	4832
@NP	hematoxylin-eosin	4832
@NP	HE	4851
@NP	All animals	4888
@NP	barrier cages	4915
@NP	a temperature - and humiditycontrolled room with ad libitum access	4932
@NP	a temperature - and humiditycontrolled room	4932
@NP	ad libitum access	4980
@NP	food and water	5001
@NP	This study	5017
@NP	the Animal Care Committee	5044
@NP	the Graduate School of Agricultural and Life Sciences	5073
@NP	the Graduate School	5073
@NP	Agricultural and Life Sciences	5096
@NP	The University of Tokyo -LRB- approval number : P11-523 -RRB-	5128
@NP	The University	5128
@NP	Tokyo -LRB- approval number : P11-523 -RRB-	5146
@NP	Tokyo	5146
@NP	approval number : P11-523	5153
@NP	approval number	5153
@NP	P11-523	5170
@NP	Culture of OECs : A total of nine cultures	5180
@NP	Culture	5180
@NP	OECs : A total of nine cultures	5191
@NP	OECs	5191
@NP	A total of nine cultures	5197
@NP	A total	5197
@NP	nine cultures	5208
@NP	the following evaluations and transplantation	5235
@NP	the following evaluations	5235
@NP	transplantation	5265
@NP	three of the nine cultures	5282
@NP	three	5282
@NP	the nine cultures	5291
@NP	reverse transcription-polymerase chain reaction -LRB- RT-PCR -RRB-	5323
@NP	reverse transcription-polymerase chain reaction	5323
@NP	RT-PCR	5372
@NP	three cultures	5381
@NP	substrate zymography	5410
@NP	three cultures	5432
@NP	transplantation in SCI model rats	5461
@NP	transplantation	5461
@NP	SCI model rats	5480
@NP	a small portion from five cultures	5500
@NP	a small portion	5500
@NP	five cultures	5521
@NP	the evaluation of the purity of the cultured OECs	5548
@NP	the evaluation	5548
@NP	the purity of the cultured OECs	5566
@NP	the purity	5566
@NP	the cultured OECs	5580
@NP	the	5580
@NP	OECs	5593
@NP	Four rats	5599
@NP	a time	5628
@NP	i.e. , eight olfactory bulbs	5636
@NP	i.e.	5636
@NP	eight olfactory bulbs	5642
@NP	one culture	5687
@NP	The methods of OEC culture and purification	5700
@NP	The methods	5700
@NP	OEC culture and purification	5715
@NP	those used in earlier studies , with minor modifications24 ,31	5758
@NP	earlier studies	5772
@NP	minor modifications24	5794
@NP	Eight-week-old SD rats	5821
@NP	an intraperitoneal -LRB- i.p. -RRB- injection	5867
@NP	pentobarbital -LRB- 50 mg/kg -RRB-	5906
@NP	pentobarbital	5906
@NP	50 mg/kg	5921
@NP	the loss of eyelid reflex	5947
@NP	the loss	5947
@NP	eyelid reflex	5959
@NP	the animals	5974
@NP	scarification	6022
@NP	the olfactory bulbs	6037
@NP	ice-cold Leibovitz L-15 medium -LRB- Invitrogen , Carlsbad , CA , USA -RRB-	6098
@NP	ice-cold Leibovitz L-15 medium	6098
@NP	Invitrogen	6130
@NP	Carlsbad	6142
@NP	CA , USA	6152
@NP	the remnants of adherent meningeal membranes	6168
@NP	the remnants	6168
@NP	adherent meningeal membranes	6184
@NP	the outer layer of the olfactory bulb	6232
@NP	the outer layer	6232
@NP	the olfactory bulb	6251
@NP	The bulbs	6285
@NP	a scalpel blade	6313
@NP	0.5 ml	6345
@NP	collagenase solution -LRB- 155 U collagenase/mg , Wako , Osaka -RRB- for 20 min	6355
@NP	collagenase solution -LRB- 155 U collagenase/mg , Wako , Osaka -RRB-	6355
@NP	collagenase solution	6355
@NP	155 U collagenase/mg , Wako , Osaka	6377
@NP	155 U collagenase/mg	6377
@NP	Wako , Osaka	6399
@NP	20 min	6416
@NP	37 °C in 5 % CO2	6426
@NP	37 °C	6426
@NP	5 % CO2	6434
@NP	0.5 ml of 0.25 % trypsin solution -LRB- Invitrogen -RRB-	6448
@NP	0.5 ml	6448
@NP	0.25 % trypsin solution -LRB- Invitrogen -RRB-	6458
@NP	0.25 % trypsin solution	6458
@NP	Invitrogen	6482
@NP	the mixture	6509
@NP	37 °C for another 15 min	6538
@NP	37 °C	6538
@NP	another 15 min	6547
@NP	incubation	6569
@NP	the samples	6581
@NP	10 ml of DMEM	6608
@NP	10 ml	6608
@NP	DMEM	6617
@NP	10 % fetal bovine serum -LRB- FBS ; Invitrogen -RRB-	6633
@NP	10 % fetal bovine serum	6633
@NP	FBS ; Invitrogen	6657
@NP	FBS	6657
@NP	Invitrogen	6662
@NP	1 mM glutamine -LRB- Nissui Pharmaceutical , Tokyo -RRB-	6675
@NP	1 mM glutamine	6675
@NP	Nissui Pharmaceutical	6691
@NP	Tokyo	6714
@NP	2 % gentamicin	6726
@NP	Sigma	6741
@NP	St.	6748
@NP	Louis , MO , USA -RRB-	6752
@NP	Louis	6752
@NP	MO	6759
@NP	USA	6763
@NP	medium -LRB- DM -LRB- + -RRB- -RRB-	6781
@NP	medium	6781
@NP	DM -LRB- + -RRB-	6789
@NP	DM	6789
@NP	-LRB- + -RRB-	6792
@NP	220 × g	6809
@NP	5 min	6821
@NP	The pellets	6828
@NP	1 ml	6860
@NP	soybean trypsin inhibitor	6868
@NP	0.25 mg/ml ; Sigma	6895
@NP	0.25 mg/ml	6895
@NP	Sigma	6907
@NP	bovine pancreas DNase	6918
@NP	0.04 mg/ml ; Sigma	6941
@NP	0.04 mg/ml	6941
@NP	Sigma	6953
@NP	solution containing bovine serum albumin -LRB- 0.3 mg/ml ; Sigma -RRB-	6960
@NP	solution	6960
@NP	bovine serum albumin -LRB- 0.3 mg/ml ; Sigma -RRB-	6980
@NP	bovine serum albumin	6980
@NP	0.3 mg/ml ; Sigma	7002
@NP	0.3 mg/ml	7002
@NP	Sigma	7013
@NP	10 times	7036
@NP	a 5-ml glass pipette	7051
@NP	21 - and 23 -	7100
@NP	21	7100
@NP	23	7108
@NP	needles with a 1-ml syringe	7118
@NP	needles	7118
@NP	a 1-ml syringe	7131
@NP	The samples	7161
@NP	10 ml of DM -LRB- + -RRB- and spun at 220 × g for 5 min	7195
@NP	10 ml	7195
@NP	DM -LRB- + -RRB- and spun at 220 × g for 5 min	7204
@NP	DM	7204
@NP	+	7208
@NP	220 × g	7223
@NP	5 min	7235
@NP	The resulting cell pellets	7242
@NP	+	7293
@NP	containing	7296
@NP	2 μM forskolin -LRB- Sigma -RRB-	7307
@NP	2 μM forskolin	7307
@NP	Sigma	7323
@NP	20 ng / ml neuregulin-1 -LRB- R & D Systems , Minneapolis , MN , USA -RRB-	7334
@NP	20 ng / ml neuregulin-1	7334
@NP	ml neuregulin-1	7341
@NP	R & D Systems	7358
@NP	R	7358
@NP	D Systems	7362
@NP	Minneapolis , MN , USA	7373
@NP	Minneapolis	7373
@NP	MN	7386
@NP	USA	7390
@NP	a growth medium -LRB- GM -LRB- + -RRB- -RRB-	7398
@NP	a growth	7398
@NP	medium -LRB- GM -LRB- + -RRB- -RRB-	7407
@NP	medium	7407
@NP	GM	7415
@NP	+	7419
@NP	90-mm-dia	7442
@NP	dishes at 1 × 106 cells/dish in 10 ml of GM -LRB- + -RRB- for 24 hr .	7453
@NP	dishes at 1	7453
@NP	dishes	7453
@NP	1	7463
@NP	× 106 cells/dish in 10 ml of GM -LRB- + -RRB- for 24 hr	7465
@NP	× 106 cells/dish in 10 ml of GM -LRB- + -RRB- for 24	7465
@NP	× 106 cells/dish	7465
@NP	10 ml of GM -LRB- + -RRB- for 24	7485
@NP	10 ml	7485
@NP	+	7498
@NP	for 24	7501
@NP	hr	7508
@NP	the 24 hrs incubation	7518
@NP	the supernatant containing floating cells	7541
@NP	the supernatant	7541
@NP	floating cells	7568
@NP	other dishes	7602
@NP	48 hr	7633
@NP	this incubation	7646
@NP	the supernatant containing floating cells	7663
@NP	the supernatant	7663
@NP	floating cells	7690
@NP	poly-L-lysine-coated dishes and 5 ml of GM -LRB- + -RRB- was added to each dish	7724
@NP	poly-L-lysine-coated dishes	7724
@NP	5 ml of GM -LRB- + -RRB- was added to each dish	7756
@NP	5 ml	7756
@NP	GM	7764
@NP	+	7768
@NP	each dish	7784
@NP	Cultures	7795
@NP	37 °C in 5 % CO2	7823
@NP	37 °C	7823
@NP	5 % CO2	7831
@NP	10 ml of culture medium	7843
@NP	10 ml	7843
@NP	culture medium	7852
@NP	5 ml of GM -LRB- + -RRB- at 6 days in vitro -LRB- DIV -RRB-	7885
@NP	5 ml of GM -LRB- + -RRB- at 6 days in vitro	7885
@NP	5 ml	7885
@NP	+	7897
@NP	at 6	7900
@NP	days	7905
@NP	DIV	7920
@NP	that	7932
@NP	the culture medium	7938
@NP	every 2-3 days	7969
@NP	the culture	7990
@NP	confluence	8010
@NP	confluence	8037
@NP	the cells	8049
@NP	RNA extraction , substrate zymography , and transplantation	8073
@NP	RNA extraction	8073
@NP	substrate zymography	8089
@NP	transplantation	8115
@NP	SCI model rats	8134
@NP	The purity of the cultured OECs	8150
@NP	The purity	8150
@NP	the cultured OECs	8164
@NP	the	8164
@NP	OECs	8177
@NP	monoclonal mouse anti-p75NTR	8225
@NP	1 : 100 ; Millipore , Temecula , CA , USA	8255
@NP	1 : 100	8255
@NP	Millipore , Temecula , CA , USA	8264
@NP	1 : 200 ; Jackson Immunoresearch Laboratories , West Grove , PA , USA	8330
@NP	1 : 200	8330
@NP	Jackson Immunoresearch Laboratories , West Grove , PA , USA	8339
@NP	Jackson Immunoresearch Laboratories	8339
@NP	West Grove	8376
@NP	PA	8388
@NP	USA	8392
@NP	The results of immunocytochemistry	8398
@NP	The results	8398
@NP	immunocytochemistry	8413
@NP	a purity of ＞ 95 % -LRB- data not shown -RRB-	8441
@NP	a purity	8441
@NP	＞ 95 % -LRB- data not shown -RRB-	8453
@NP	＞ 95 %	8453
@NP	data not shown	8460
@NP	data	8460
@NP	RT-PCR	8477
@NP	We	8485
@NP	RT-PCR	8493
@NP	the mRNA expressions of MMPs in the OECs	8511
@NP	the mRNA expressions	8511
@NP	MMPs in the OECs	8535
@NP	MMPs	8535
@NP	the OECs	8543
@NP	the experimental control	8557
@NP	the mRNA of HT-1080 , a human fibrosarcoma cell line ,	8583
@NP	the mRNA	8583
@NP	HT-1080 , a human fibrosarcoma cell line ,	8595
@NP	HT-1080	8595
@NP	a human fibrosarcoma cell line	8604
@NP	RT-PCR	8658
@NP	Total RNA	8666
@NP	OECs	8695
@NP	the RNeasy Mini Kit -LRB- Qiagen , Hilden , Germany -RRB-	8706
@NP	the RNeasy Mini Kit	8706
@NP	Qiagen	8727
@NP	Hilden	8735
@NP	Germany	8743
@NP	the manufacturer 's protocol	8765
@NP	the manufacturer 's	8765
@NP	the procedure	8801
@NP	genomic DNA	8816
@NP	DNase I -LRB- Qiagen -RRB-	8844
@NP	cDNA	8865
@NP	5 μg of total RNA	8891
@NP	5 μg	8891
@NP	total RNA	8899
@NP	SuperScriptTM III	8915
@NP	Reverse Transcriptase -LRB- Invitrogen -RRB-	8933
@NP	Reverse Transcriptase	8933
@NP	Invitrogen	8956
@NP	10 mM dNTP Mix -LRB- Invitrogen -RRB-	8972
@NP	10 mM dNTP Mix	8972
@NP	Invitrogen	8988
@NP	The cDNA	9001
@NP	specific primers of Mmp2 , Mmp3 , Mmp9 and glyceraldehyde-3	9049
@NP	specific primers	9049
@NP	Mmp2 , Mmp3 , Mmp9 and glyceraldehyde-3	9069
@NP	phosohate dehydrogenase -LRB- Gapdh -RRB-	9108
@NP	phosohate dehydrogenase	9108
@NP	Gapdh	9133
@NP	We	9141
@NP	the forward and reverse primers	9153
@NP	Mmp2 , Mmp3 , and Mmp9	9189
@NP	Primer 3 software	9216
@NP	the primer sets for Gapdh given in a previous report were used14	9239
@NP	the primer	9239
@NP	Gapdh given in a previous report	9259
@NP	Gapdh	9259
@NP	a previous report	9274
@NP	used14	9297
@NP	Table 1	9306
@NP	The following PCR cycling	9316
@NP	94 °C for 2 min	9363
@NP	94 °C	9363
@NP	2 min	9372
@NP	35 cycles of 94 °C for 1 min , 60 °C for 1 min , and 72 °C for 2 min	9389
@NP	35 cycles of 94 °C for 1 min	9389
@NP	35 cycles	9389
@NP	94 °C for 1 min	9402
@NP	94 °C	9402
@NP	1 min	9411
@NP	60 °C for 1 min	9418
@NP	60 °C	9418
@NP	1 min	9427
@NP	72 °C for 2 min	9438
@NP	72 °C	9438
@NP	2 min	9447
@NP	PCR products	9454
@NP	0.005 %	9484
@NP	ethidium	9491
@NP	agarose gels	9515
@NP	a Printgraph ® device -LRB- Atto , Tokyo -RRB-	9557
@NP	a Printgraph ® device	9557
@NP	Atto	9579
@NP	Tokyo	9585
@NP	Substrate zymography	9593
@NP	Substrate zymography	9615
@NP	the secretion of MMP-2 , -3 , and -9 from OECs	9660
@NP	the secretion	9660
@NP	MMP-2 , -3 , and -9 from OECs	9677
@NP	MMP-2 , -3 , and -9	9677
@NP	OECs	9700
@NP	Primary OECs	9706
@NP	a poly-L-lysine-coated 60-mm-dia	9738
@NP	dish at 2 × 10	9772
@NP	dish	9772
@NP	2 × 10	9780
@NP	6 cells/dish in 6 ml of GM -LRB- + -RRB-	9787
@NP	6 cells/dish	9787
@NP	6 ml of GM -LRB- + -RRB-	9803
@NP	6 ml	9803
@NP	GM -LRB- + -RRB-	9811
@NP	GM	9811
@NP	+	9815
@NP	1 DIV	9825
@NP	the OECs	9832
@NP	+	9865
@NP	without FBS -LRB- DM -LRB- - -RRB- -RRB- and then incubated in 6 ml of DM	9868
@NP	FBS -LRB- DM -LRB- - -RRB- -RRB- and then	9876
@NP	FBS -LRB- DM -LRB- - -RRB- -RRB-	9876
@NP	FBS	9876
@NP	DM	9881
@NP	-	9885
@NP	then	9893
@NP	incubated	9898
@NP	6 ml of DM	9911
@NP	6 ml	9911
@NP	DM	9919
@NP	-	9923
@NP	2 μM forskolin -LRB- Sigma -RRB- -LRB- GM -LRB- - -RRB- -RRB-	9937
@NP	2 μM forskolin -LRB- Sigma -RRB-	9937
@NP	2 μM forskolin	9937
@NP	Sigma	9953
@NP	GM -LRB- - -RRB-	9961
@NP	GM	9961
@NP	-LRB- - -RRB-	9964
@NP	72 hr	9973
@NP	incubation	9986
@NP	the culture media	9998
@NP	OEC-conditioned media -LRB- OEC-CM -RRB-	10034
@NP	OEC-conditioned media	10034
@NP	OEC-CM	10057
@NP	4 °C , 1000 × g for 10 min	10084
@NP	4 °C	10084
@NP	1000 × g for 10 min	10089
@NP	1000 × g	10089
@NP	10 min	10102
@NP	floating cells	10119
@NP	sodium dodecyl	10155
@NP	sulfate-polyacrylamide gel electrophoresis -LRB- SDS-PAGE -RRB-	10170
@NP	sulfate-polyacrylamide gel electrophoresis	10170
@NP	SDS-PAGE	10214
@NP	the OEC-CM	10225
@NP	an Amicon ® Ultra Centrifugal Filter Device -LRB- Millipore -RRB-	10268
@NP	an Amicon ® Ultra Centrifugal Filter Device	10268
@NP	Millipore	10312
@NP	an equal volume of OEC-CM	10328
@NP	an equal volume	10328
@NP	OEC-CM	10347
@NP	non-reducing	10371
@NP	3 × sample buffer	10384
@NP	Equal volumes of samples	10402
@NP	Equal volumes	10402
@NP	samples	10419
@NP	a 7.5 % SDS gel	10445
@NP	1 mg/ml gelatin -LRB- Sigma -RRB- for MMP-2 and -9	10471
@NP	1 mg/ml gelatin -LRB- Sigma -RRB-	10471
@NP	1 mg/ml gelatin	10471
@NP	Sigma	10488
@NP	MMP-2 and -9	10499
@NP	MMP-2	10499
@NP	-9	10509
@NP	0.5 mg/ml casein -LRB- Sigma -RRB- for MMP-3	10516
@NP	0.5 mg/ml casein -LRB- Sigma -RRB-	10516
@NP	0.5 mg/ml casein	10516
@NP	Sigma	10534
@NP	MMP-3	10545
@NP	The gels	10552
@NP	15 min	10583
@NP	10 min on a shaker at room temperature	10604
@NP	10 min	10604
@NP	a shaker at room temperature	10614
@NP	a shaker	10614
@NP	room temperature	10626
@NP	buffer	10648
@NP	2.5 % t-octylphenoxypolyethoxyethanol -LRB- Triton-X ; Sigma -RRB-	10666
@NP	2.5 % t-octylphenoxypolyethoxyethanol	10666
@NP	Triton-X ; Sigma	10704
@NP	Triton-X	10704
@NP	Sigma	10714
@NP	100 mM Tris-HCl -LRB- pH 7.5 -RRB-	10722
@NP	100 mM Tris-HCl	10722
@NP	pH 7.5	10739
@NP	5 μM ZnCl2	10748
@NP	5 mM CaCl2	10764
@NP	that	10782
@NP	the gels	10788
@NP	48 hrs at 37 °C in re-activation buffer	10816
@NP	48 hrs	10816
@NP	37 °C in re-activation buffer	10826
@NP	37 °C	10826
@NP	re-activation buffer	10834
@NP	100 mM Tris-HCl -LRB- pH 7.5 -RRB- , 5 μM ZnCl2 , and 5 mM CaCl2	10866
@NP	100 mM Tris-HCl -LRB- pH 7.5 -RRB-	10866
@NP	100 mM Tris-HCl	10866
@NP	pH 7.5	10883
@NP	5 μM ZnCl2	10892
@NP	5 mM CaCl2	10908
@NP	incubation	10926
@NP	the gels	10938
@NP	0.1 % Coomassie Brilliant Blue R-250	10965
@NP	0.1 %	10965
@NP	a solution of formic acid/methanol/water -LRB- 1 : 30 : 70 -RRB-	11018
@NP	a solution	11018
@NP	formic acid/methanol/water -LRB- 1 : 30 : 70 -RRB-	11032
@NP	formic acid/methanol/water	11032
@NP	1 : 30 : 70	11060
@NP	1	11060
@NP	30 : 70	11064
@NP	The presence of MMPs	11074
@NP	The presence	11074
@NP	MMPs	11090
@NP	clear bands	11107
@NP	a dark background	11127
@NP	we	11150
@NP	the co-migration of bands with MMPs	11162
@NP	the co-migration	11162
@NP	bands with MMPs	11182
@NP	bands	11182
@NP	MMPs	11193
@NP	the conditioned media of rat meningeal fibroblasts -LRB- mFB-CM -RRB-	11203
@NP	the conditioned media	11203
@NP	rat meningeal fibroblasts -LRB- mFB-CM -RRB-	11228
@NP	rat meningeal fibroblasts	11228
@NP	mFB-CM	11255
@NP	HT-1080 cells	11272
@NP	a	11297
@NP	molecular weight standard	11307
@NP	Bio	11334
@NP	Rad Laboratories , Hercules , CA , USA	11339
@NP	Rad Laboratories	11339
@NP	Hercules	11357
@NP	CA	11367
@NP	USA	11371
@NP	Conditioned media of HT-1080 -LRB- HT-1080-CM -RRB-	11377
@NP	Conditioned media of HT-1080	11377
@NP	Conditioned media	11377
@NP	HT-1080	11398
@NP	HT-1080-CM	11407
@NP	a positive control for gelatin zymography	11438
@NP	a positive control	11438
@NP	gelatin zymography	11461
@NP	a technical control	11492
@NP	Conditioned media from mFBs	11513
@NP	Conditioned media	11513
@NP	mFBs	11536
@NP	a molecular weight control of rat MMP-2 and -9	11554
@NP	a molecular weight control	11554
@NP	rat MMP-2 and -9	11584
@NP	the HT-1080 line	11609
@NP	human cells	11647
@NP	The gels	11660
@NP	a digital scanner	11685
@NP	the images of gels	11708
@NP	the images	11708
@NP	gels	11722
@NP	gray-scale	11745
@NP	Adobe Photoshop 6.0	11762
@NP	Preparation of contusion model	11783
@NP	Preparation	11783
@NP	contusion model	11798
@NP	Ten-week-old SD rats	11815
@NP	an i.p. injection of pentobarbital -LRB- 50 mg/kg -RRB-	11859
@NP	an i.p. injection	11859
@NP	pentobarbital -LRB- 50 mg/kg -RRB-	11880
@NP	pentobarbital	11880
@NP	50 mg/kg	11895
@NP	a dorsal laminectomy	11910
@NP	the T10 vertebral level -LRB- Fig. 1A -RRB-	11948
@NP	the T10 vertebral level	11948
@NP	Fig. 1A	11973
@NP	The IH-0400 Impactor	11983
@NP	Precision Systems and Instrumentation , Fairfax , VA , USA	12005
@NP	Precision Systems	12005
@NP	Instrumentation , Fairfax , VA , USA	12027
@NP	a severe -LRB- 250 kdyn ; 1dyn ＝ 10 ∧ -5 N -RRB- contusion injury1	12079
@NP	250 kdyn ; 1dyn ＝ 10 ∧ -5 N	12089
@NP	250 kdyn	12089
@NP	1dyn ＝ 10 ∧ -5 N	12099
@NP	1dyn ＝	12099
@NP	10 ∧ -5 N	12106
@NP	10 ∧	12106
@NP	-5 N	12109
@NP	impact	12141
@NP	the overlying muscles	12149
@NP	skin opening	12188
@NP	The animals	12213
@NP	a subcutaneous administration	12234
@NP	20 mg/kg cefazolin sodium for the first 3 days post-injury -LRB- dpi -RRB-	12267
@NP	20 mg/kg cefazolin sodium for the first 3 days post-injury	12267
@NP	20 mg/kg cefazolin sodium for the first 3 days	12267
@NP	20 mg/kg cefazolin sodium	12267
@NP	the first 3 days	12297
@NP	dpi	12327
@NP	their bladders	12337
@NP	twice a day	12376
@NP	a bladder reflex	12394
@NP	Transplantation of OECs : OEC transplantation	12425
@NP	Transplantation	12425
@NP	OECs : OEC transplantation	12444
@NP	OECs	12444
@NP	OEC transplantation	12450
@NP	14-15 dpi	12487
@NP	transplantation	12507
@NP	OECs	12524
@NP	fluorescent labeling	12538
@NP	described5	12562
@NP	OECs	12575
@NP	10 μg/ml	12596
@NP	Hoechst 33342 -LRB- Sigma -RRB-	12605
@NP	Hoechst 33342	12605
@NP	Sigma	12620
@NP	DM	12630
@NP	+	12633
@NP	10 min and then	12640
@NP	10 min	12640
@NP	then	12651
@NP	+	12674
@NP	at a density of 5 × 104 cells/μl	12677
@NP	at a density of 5 × 104	12677
@NP	at	12677
@NP	density	12682
@NP	5	12693
@NP	104	12697
@NP	cells/μl	12701
@NP	Three of six SCI rats	12711
@NP	Three	12711
@NP	six SCI rats	12720
@NP	OEC suspension -LRB- = the OEC group -RRB-	12752
@NP	OEC suspension	12752
@NP	= the OEC group	12768
@NP	=	12768
@NP	the OEC group	12770
@NP	the other three	12789
@NP	a DM -LRB- + -RRB- injection	12819
@NP	+	12824
@NP	a negative control -LRB- = the media group -RRB-	12840
@NP	a negative control	12840
@NP	= the media group	12860
@NP	=	12860
@NP	the media group	12862
@NP	The animals	12880
@NP	50 mg/kg , i.p.	12930
@NP	50 mg/kg	12930
@NP	the T10 level of the spinal cord	12951
@NP	the T10 level	12951
@NP	the spinal cord	12968
@NP	an incision in the dura matter	13013
@NP	an incision	13013
@NP	the dura matter	13028
@NP	the animal	13045
@NP	a stereotaxic instrument	13074
@NP	rats -LRB- SR-6R ; Narishige Scientific Instrument Laboratory , Tokyo -RRB-	13103
@NP	rats	13103
@NP	SR-6R ; Narishige Scientific Instrument Laboratory , Tokyo	13109
@NP	SR-6R	13109
@NP	Narishige Scientific Instrument Laboratory , Tokyo	13116
@NP	Narishige Scientific Instrument Laboratory	13116
@NP	Tokyo	13160
@NP	the points of transplantation	13172
@NP	the points	13172
@NP	transplantation	13186
@NP	a microinjector -LRB- IMS-3 ; Narishige -RRB-	13221
@NP	a microinjector	13221
@NP	IMS-3 ; Narishige	13238
@NP	IMS-3	13238
@NP	Narishige	13245
@NP	The cell	13257
@NP	suspension or DM	13266
@NP	+	13283
@NP	the injured spinal cord	13304
@NP	a 10-μl microsyringe	13334
@NP	Hamilton	13356
@NP	Reno	13366
@NP	NV , USA	13372
@NP	a 30-gauge needle	13385
@NP	Becton , Dickinson and Co. , Franklin Lakes , NJ , USA	13404
@NP	Becton , Dickinson and Co.	13404
@NP	Franklin Lakes	13431
@NP	NJ	13447
@NP	USA	13451
@NP	Symmetrical injections about the vein running on the midline of the spinal cord	13457
@NP	Symmetrical injections	13457
@NP	the vein running on the midline of the spinal cord	13486
@NP	the vein	13486
@NP	the midline of the spinal cord	13506
@NP	the midline	13506
@NP	the spinal cord	13521
@NP	the lesion epicenter and 1 mm cranial and caudal from the epicenter	13555
@NP	the lesion epicenter and 1 mm cranial	13555
@NP	the lesion epicenter	13555
@NP	1 mm cranial	13580
@NP	caudal from the epicenter	13597
@NP	caudal	13597
@NP	the epicenter	13609
@NP	i.e. , a total of six injections	13624
@NP	i.e.	13624
@NP	a total of six injections	13630
@NP	a total	13630
@NP	six injections	13641
@NP	Fig. 1B	13667
@NP	One μl of cell suspension	13677
@NP	One μl	13677
@NP	cell suspension	13687
@NP	each point at 1-mm depth	13723
@NP	each point	13723
@NP	1-mm depth	13737
@NP	the surface of the spinal cord -LRB- Fig. 1C -RRB-	13753
@NP	the surface	13753
@NP	the spinal cord -LRB- Fig. 1C -RRB-	13768
@NP	the spinal cord	13768
@NP	Fig. 1C	13785
@NP	reflux of the suspension	13804
@NP	reflux	13804
@NP	the suspension	13814
@NP	the injection site	13834
@NP	1 min	13854
@NP	each injection	13874
@NP	the needle	13894
@NP	place for another 1 min	13917
@NP	place	13917
@NP	another 1 min	13927
@NP	the injection	13947
@NP	transplantation	13982
@NP	muscles and skin	13999
@NP	the same manner	14031
@NP	that used for the preparation of injury	14050
@NP	that	14050
@NP	the preparation of injury	14064
@NP	the preparation	14064
@NP	injury	14083
@NP	the animals	14095
@NP	warmed cages overnight	14134
@NP	The administration of antibiotics and manual urination	14158
@NP	The administration	14158
@NP	antibiotics and manual urination	14180
@NP	antibiotics	14180
@NP	manual urination	14196
@NP	the same manner	14231
@NP	that used for the preparation of injury	14250
@NP	that	14250
@NP	the preparation of injury	14264
@NP	the preparation	14264
@NP	injury	14283
@NP	Tissue staining and immunofluorescence	14291
@NP	The animals	14331
@NP	7-8 days	14362
@NP	transplantation -LRB- 21-22 dpi -RRB-	14377
@NP	transplantation	14377
@NP	21-22 dpi	14394
@NP	the spinal cord tissues	14410
@NP	One 13-week-old female SD rat	14449
@NP	One	14449
@NP	13-week-old female SD rat	14453
@NP	intact spinal cord tissue	14509
@NP	deep anesthesia by an overdose of pentobarbital -LRB- i.p. -RRB-	14542
@NP	deep anesthesia	14542
@NP	an overdose of pentobarbital	14561
@NP	an overdose	14561
@NP	the rats	14598
@NP	4 % paraformaldehyde-phosphatebuffered saline -LRB- PFA-PBS -RRB-	14641
@NP	4 % paraformaldehyde-phosphatebuffered saline	14641
@NP	PFA-PBS	14687
@NP	perfusion	14703
@NP	the T8-T12 level of the spinal cord	14714
@NP	the T8-T12 level	14714
@NP	the spinal cord	14734
@NP	ice-cold PBS	14790
@NP	The meninges	14804
@NP	the spinal roots	14844
@NP	stereomicroscopic observation	14880
@NP	the tissues	14927
@NP	further fixed in 4 % PFA-PBS at 4 °C overnight	14944
@NP	further	14944
@NP	4 % PFA-PBS at 4 °C	14961
@NP	4 % PFA-PBS	14961
@NP	4 °C	14975
@NP	the fixed tissues	14999
@NP	PBS solution	15038
@NP	20 % -LRB- w/v -RRB- sucrose	15062
@NP	w/v	15067
@NP	4 °C for more than 6 hr	15083
@NP	4 °C	15083
@NP	more than 6 hr	15091
@NP	Further equilibration	15107
@NP	PBS solution	15146
@NP	30 % -LRB- w/v -RRB-	15170
@NP	30 %	15170
@NP	w/v	15175
@NP	sucrose for 48 hr	15180
@NP	sucrose	15180
@NP	48 hr	15192
@NP	equilibration	15205
@NP	10 mm of spinal cord centered on the lesion epicenter	15220
@NP	10 mm	15220
@NP	spinal cord centered on the lesion epicenter	15229
@NP	spinal cord	15229
@NP	the lesion epicenter	15253
@NP	a scalpel blade	15287
@NP	The tissues	15304
@NP	Tissue-Tek ® -LRB- OCT -RRB- compound -LRB- Sakura Finetek Japan , Tokyo -RRB-	15333
@NP	Tissue-Tek ® -LRB- OCT -RRB- compound	15333
@NP	Tissue-Tek ® -LRB- OCT -RRB-	15333
@NP	Tissue-Tek ®	15333
@NP	OCT	15346
@NP	Sakura Finetek Japan	15361
@NP	Tokyo	15383
@NP	liquid nitrogen	15412
@NP	The frozen blocks	15429
@NP	a cryostat -LRB- Leica Microsystems , Tokyo -RRB-	15461
@NP	a cryostat	15461
@NP	Leica Microsystems	15473
@NP	Tokyo	15493
@NP	longitudinal horizontal sections of 14 μm thickness	15505
@NP	longitudinal horizontal sections	15505
@NP	14 μm thickness	15541
@NP	three or four sections approx. 560-μm	15562
@NP	three or four sections	15562
@NP	a glass slide -LRB- MAS-GP ; Matsunami Glass Industries , Osaka -RRB-	15627
@NP	a glass slide	15627
@NP	MAS-GP ; Matsunami Glass Industries , Osaka	15642
@NP	MAS-GP	15642
@NP	Matsunami Glass Industries , Osaka	15650
@NP	Matsunami Glass Industries	15650
@NP	Osaka	15678
@NP	Fig. 1D	15686
@NP	Several sections	15696
@NP	the intact spinal cord and the injured spinal cord of the media group	15716
@NP	the intact spinal cord	15716
@NP	the injured spinal cord of the media group	15743
@NP	the injured spinal cord	15743
@NP	the media group	15770
@NP	hematoxylin and eosin -LRB- HE -RRB-	15802
@NP	hematoxylin and eosin	15802
@NP	HE	15825
@NP	the degree of injury	15841
@NP	the degree	15841
@NP	injury	15855
@NP	the power of 250 kDyne	15865
@NP	the power	15865
@NP	250 kDyne	15878
@NP	immunofluorescence	15893
@NP	the slides	15913
@NP	Tris-buffered saline	15941
@NP	0.1 %	15973
@NP	polyoxyethylene sorbitan monolaurate -LRB- Tween ® 20 ; Sigma -RRB-	15978
@NP	polyoxyethylene sorbitan monolaurate	15978
@NP	Tween ® 20 ; Sigma	16016
@NP	Tween ® 20	16016
@NP	Sigma	16027
@NP	TBS-T	16035
@NP	three times	16042
@NP	5 min	16058
@NP	each time	16064
@NP	normal goat serum -LRB- NGS -RRB- diluted in TBS-T for 1 hr at room temperature	16099
@NP	normal goat serum -LRB- NGS -RRB-	16099
@NP	normal goat serum	16099
@NP	NGS	16118
@NP	TBS-T for 1 hr	16134
@NP	TBS-T	16134
@NP	1 hr	16144
@NP	room temperature	16152
@NP	The slides	16170
@NP	primary antibodies	16206
@NP	TBS-T	16236
@NP	5 % NGS	16253
@NP	4 °C	16263
@NP	overnight ; 1	16267
@NP	overnight	16267
@NP	1	16278
@NP	250 polyclonal rabbit anti-MMP-2 -LRB- Abcam , Cambridge , UK -RRB- and 1	16282
@NP	250 polyclonal rabbit anti-MMP-2 -LRB- Abcam , Cambridge , UK -RRB-	16282
@NP	250 polyclonal rabbit anti-MMP-2	16282
@NP	Abcam	16316
@NP	Cambridge	16323
@NP	UK	16334
@NP	1	16342
@NP	300 monoclonal mouse anti-neurocan -LRB- Millipore -RRB-	16346
@NP	300 monoclonal mouse	16346
@NP	anti-neurocan -LRB- Millipore -RRB-	16367
@NP	The slides	16394
@NP	then washed with TBS-T three times for 5 min each time , and incubated with 1	16410
@NP	then	16410
@NP	TBS-T three times for 5 min	16427
@NP	TBS-T	16427
@NP	three times	16433
@NP	5 min	16449
@NP	each time	16455
@NP	1	16485
@NP	200 secondary antibodies for 1 hr at room temperature	16489
@NP	200 secondary antibodies	16489
@NP	1 hr at room temperature	16518
@NP	1 hr	16518
@NP	room temperature	16526
@NP	Cy3-conjugated goat anti-mouse -LRB- Jackson Immunoresearch Laboratories -RRB-	16544
@NP	Cy3-conjugated goat anti-mouse	16544
@NP	Jackson Immunoresearch Laboratories	16576
@NP	FITC-conjugated goat anti-rabbit -LRB- Invitrogen -RRB-	16617
@NP	FITC-conjugated goat anti-rabbit	16617
@NP	Invitrogen	16651
@NP	incubation	16670
@NP	the slides	16682
@NP	TBS-T three times for 5 min	16710
@NP	TBS-T	16710
@NP	three times	16716
@NP	5 min	16732
@NP	each time	16738
@NP	Medium	16772
@NP	Fluorescent Microscopy -LRB- KPL , Gaithersburg , MD , USA -RRB-	16783
@NP	Fluorescent Microscopy	16783
@NP	KPL	16807
@NP	Gaithersburg	16812
@NP	MD , USA	16826
@NP	Quantitative analysis of fluorescence-stained images	16836
@NP	Quantitative analysis	16836
@NP	fluorescence-stained images	16861
@NP	the MMP-2 expression and neurocan degradation	16902
@NP	the transplantation sites	16955
@NP	we	16982
@NP	laser	16990
@NP	confocal microscopy	17005
@NP	We	17026
@NP	the degradation of neurocan	17039
@NP	the degradation	17039
@NP	neurocan	17058
@NP	the fluorescent signal intensity of neurocan	17080
@NP	the fluorescent signal intensity	17080
@NP	neurocan	17116
@NP	Fluorescence images of immunostained slides	17126
@NP	Fluorescence images	17126
@NP	immunostained slides	17149
@NP	the FluoView300 laser scanning confocal microscope -LRB- Olympus , Tokyo -RRB-	17194
@NP	the FluoView300 laser scanning confocal microscope	17194
@NP	Olympus	17246
@NP	Tokyo	17255
@NP	A 100 × objective lens	17263
@NP	the observation of MMP-2	17298
@NP	the observation	17298
@NP	MMP-2	17317
@NP	a 10 × objective lens	17328
@NP	neurocan	17362
@NP	the camera gain	17377
@NP	fixed values for all samples	17411
@NP	fixed values	17411
@NP	all samples	17428
@NP	The region of interest -LRB- ROI -RRB-	17441
@NP	The region of interest	17441
@NP	The region	17441
@NP	interest	17455
@NP	ROI	17465
@NP	a field	17485
@NP	the most intensive accumulation of Hoechst 33342-positive nuclei	17505
@NP	the most intensive accumulation	17505
@NP	Hoechst 33342-positive nuclei	17540
@NP	the MMP-2 secretion	17582
@NP	transplanted OECs and neurocan degradation around transplanted OECs	17605
@NP	transplanted OECs	17605
@NP	neurocan degradation around transplanted OECs	17627
@NP	neurocan degradation	17627
@NP	transplanted OECs	17655
@NP	The ROI in the media group	17674
@NP	The ROI	17674
@NP	the media group	17685
@NP	the counterpart site	17716
@NP	The method	17738
@NP	neurocan degradation	17765
@NP	the digital images was	17791
@NP	the digital images	17791
@NP	described1	17817
@NP	a minor modification	17834
@NP	Images of neurocan stained with Cy3	17856
@NP	Images	17856
@NP	neurocan stained with Cy3	17866
@NP	neurocan	17866
@NP	Cy3	17888
@NP	gray-scale	17910
@NP	the mean intensity value -LRB- MIV -RRB- of each image	17926
@NP	the mean intensity value -LRB- MIV -RRB-	17926
@NP	the mean intensity value	17926
@NP	MIV	17952
@NP	each image	17960
@NP	the histogram of the signal intensity	17991
@NP	the histogram	17991
@NP	the signal intensity	18008
@NP	Image-J software	18035
@NP	The results of the quantification	18053
@NP	The results	18053
@NP	the quantification	18068
@NP	means	18104
@NP	SD	18112
@NP	Statistical analysis	18116
@NP	We	18138
@NP	Student 's	18146
@NP	the MIVs of neurocan expression	18174
@NP	the MIVs	18174
@NP	neurocan expression	18186
@NP	the media and OEC groups	18209
@NP	p-values ＜ 0.05	18239
@NP	p-values	18239
@NP	＜ 0.05	18248
@NP	Results Table 1 .	18285
@NP	Results	18285
@NP	Table 1	18293
@NP	Primer sequences	18302
@NP	RT-PCRa	18323
@NP	the mRNA expressions of MMPsb -RRB- in OECsc	18343
@NP	the mRNA	18343
@NP	expressions of MMPsb -RRB-	18352
@NP	expressions	18352
@NP	MMPsb	18367
@NP	OECsc	18377
@NP	Fig. 1	18385
@NP	Schema of the protocols .	18393
@NP	Schema	18393
@NP	the protocols	18403
@NP	A : The site of SCI induction .	18418
@NP	A : The site of SCI induction	18418
@NP	A : The site of SCI	18418
@NP	The site of SCI	18421
@NP	The site	18421
@NP	SCI	18433
@NP	induction	18437
@NP	Arrow and red circle : the site of impact .	18448
@NP	Arrow and red circle	18448
@NP	Arrow	18448
@NP	red circle	18458
@NP	the site of impact	18470
@NP	the site	18470
@NP	impact	18482
@NP	B , C : The sites of OEC transplantation in the injured spinal cord .	18490
@NP	B , C	18490
@NP	B	18490
@NP	C	18493
@NP	The sites of OEC transplantation in the injured spinal cord	18496
@NP	The sites	18496
@NP	OEC transplantation in the injured spinal cord	18509
@NP	OEC transplantation	18509
@NP	the injured spinal cord	18532
@NP	X-marks : The sites of injection .	18557
@NP	X-marks	18557
@NP	The sites of injection	18566
@NP	The sites	18566
@NP	injection	18579
@NP	D : Sectioning of spinal cord tissue .	18590
@NP	D	18590
@NP	Sectioning of spinal cord tissue	18593
@NP	Sectioning	18593
@NP	spinal cord tissue	18607
@NP	lines : Sampling point of sections	18634
@NP	lines	18634
@NP	Sampling point of sections	18641
@NP	Sampling point	18641
@NP	sections	18659
@NP	Fig. 2 .	18670
@NP	Fig.	18670
@NP	2	18675
@NP	OECs	18678
@NP	the mRNA of Mmp2 , Mmp3 and Mmp9	18693
@NP	the mRNA	18693
@NP	Mmp2 , Mmp3 and Mmp9	18705
@NP	MMP-2 protein	18738
@NP	A : The mRNA expressions of Mmp2 , Mmp3 and Mmp9 in OECs in vitro	18762
@NP	: The mRNA expressions of Mmp2 , Mmp3 and Mmp9 in OECs in vitro	18763
@NP	The mRNA expressions of Mmp2	18765
@NP	The mRNA expressions	18765
@NP	Mmp2	18789
@NP	Mmp3 and Mmp9 in OECs in vitro	18795
@NP	Mmp3 and Mmp9	18795
@NP	OECs in vitro	18812
@NP	OECs	18812
@NP	M : 50 base pair ladder .	18827
@NP	M	18827
@NP	50 base pair ladder	18830
@NP	Lanes 1 and 2 : HT-1080 -LRB- a human fibrosarcoma cell line -RRB- .	18851
@NP	Lanes 1 and 2	18851
@NP	HT-1080 -LRB- a human fibrosarcoma cell line -RRB-	18866
@NP	HT-1080	18866
@NP	a human fibrosarcoma cell line	18875
@NP	Lanes 3-5 : OECs -LRB- three independent cultures -RRB- .	18908
@NP	Lanes 3-5	18908
@NP	OECs -LRB- three independent cultures -RRB-	18919
@NP	OECs	18919
@NP	three independent cultures	18925
@NP	B	18954
@NP	Gelatinolytic activity of MMP-2	18957
@NP	Gelatinolytic activity	18957
@NP	MMP-2	18983
@NP	-9 in OEC conditioned media -LRB- OEC-CM -RRB-	18993
@NP	-9	18993
@NP	OEC conditioned media -LRB- OEC-CM -RRB-	18999
@NP	OEC	18999
@NP	media -LRB- OEC-CM -RRB-	19015
@NP	media	19015
@NP	OEC-CM	19022
@NP	Arrow : MMP-2 .	19031
@NP	Arrow	19031
@NP	MMP-2	19038
@NP	Arrowhead : MMP-9 .	19045
@NP	Arrowhead	19045
@NP	MMP-9	19056
@NP	M : molecular weight standard .	19063
@NP	M	19063
@NP	molecular weight standard	19066
@NP	Lanes 1 and 2 : OEC-CM .	19093
@NP	Lanes 1 and 2	19093
@NP	OEC-CM	19108
@NP	Lane 3 : Rat meningeal fibroblast conditioned media -LRB- mFB-CM -RRB- .	19116
@NP	Lane 3	19116
@NP	Rat meningeal fibroblast conditioned media -LRB- mFB-CM -RRB-	19124
@NP	Rat meningeal fibroblast	19124
@NP	media -LRB- mFB-CM -RRB-	19161
@NP	media	19161
@NP	mFB-CM	19168
@NP	Lane 4 : HT-1080 conditioned media -LRB- HT-1080-CM -RRB- .	19177
@NP	Lane 4	19177
@NP	HT-1080 conditioned media -LRB- HT-1080-CM -RRB-	19185
@NP	HT-1080	19185
@NP	media -LRB- HT-1080-CM -RRB-	19205
@NP	media	19205
@NP	HT-1080-CM	19212
@NP	Lane 3	19225
@NP	a molecular weight control of rat MMP-2 and -9	19244
@NP	a molecular weight control	19244
@NP	rat MMP-2 and -9	19274
@NP	rat MMP-2	19274
@NP	-9	19288
@NP	Lane 4	19296
@NP	an experimental control	19315
@NP	Fig. 3 .	19341
@NP	Fig.	19341
@NP	3	19346
@NP	Hematoxylin and eosin	19349
@NP	staining of the intact -LRB- A -RRB-	19371
@NP	staining	19371
@NP	the intact -LRB- A -RRB-	19383
@NP	injured spinal cord in the media group -LRB- B -RRB-	19402
@NP	injured spinal cord	19402
@NP	the media group -LRB- B -RRB-	19425
@NP	the media group	19425
@NP	B	19442
@NP	gm : gray matter .	19446
@NP	gm	19446
@NP	gray matter	19450
@NP	wm : white matter .	19463
@NP	wm	19463
@NP	white matter	19467
@NP	T : thorasic cord .	19481
@NP	T	19481
@NP	thorasic cord	19484
@NP	lc : lesion cavity .	19499
@NP	lc	19499
@NP	lesion cavity	19503
@NP	Arrows : lesion epicenter .	19518
@NP	Arrows	19518
@NP	lesion epicenter	19526
@NP	Bar	19544
@NP	1 mm	19550
@NP	Fig. 4 .	19557
@NP	Fig.	19557
@NP	4	19562
@NP	Immunofluorescence	19565
@NP	MMP-2	19587
@NP	the intact spinal cord -LRB- A-C -RRB-	19596
@NP	the intact spinal cord	19596
@NP	A-C	19620
@NP	the media -LRB- D-F -RRB- and OEC -LRB- G-I -RRB-	19632
@NP	the media	19632
@NP	D-F	19643
@NP	OEC	19652
@NP	G-I	19657
@NP	groups	19662
@NP	gm : gray matter .	19670
@NP	gm	19670
@NP	gray matter	19674
@NP	wm : white matter .	19687
@NP	wm	19687
@NP	white matter	19691
@NP	Red : Hoechst 33342 .	19705
@NP	Red	19705
@NP	Hoechst 33342	19710
@NP	Green : MMP-2 .	19725
@NP	Green	19725
@NP	MMP-2	19732
@NP	Bar	19739
@NP	20 μm	19745
@NP	Fig. 5 .	19753
@NP	Fig.	19753
@NP	5	19758
@NP	Immunofluorescence	19761
@NP	neurocan and the quantification	19783
@NP	neurocan	19783
@NP	the quantification	19796
@NP	fluorescent signals	19818
@NP	neurocan	19841
@NP	A-C	19851
@NP	Immunofluorescence	19856
@NP	neurocan in the intact -LRB- A -RRB- , media group -LRB- B -RRB-	19878
@NP	neurocan	19878
@NP	the intact -LRB- A -RRB- , media group -LRB- B -RRB-	19890
@NP	the intact -LRB- A -RRB- , media group	19890
@NP	-LRB- A -RRB- , media	19901
@NP	-LRB- A -RRB-	19901
@NP	media	19906
@NP	B	19919
@NP	OEC group -LRB- C -RRB-	19927
@NP	OEC group	19927
@NP	C	19937
@NP	gm : gray matter .	19941
@NP	gm	19941
@NP	gray matter	19945
@NP	wm : white matter .	19958
@NP	wm	19958
@NP	white matter	19962
@NP	Red : neurocan .	19976
@NP	Red	19976
@NP	neurocan	19981
@NP	Blue : Hoechst 33342 .	19991
@NP	Blue	19991
@NP	Hoechst 33342	19997
@NP	Bar	20012
@NP	200 μm	20018
@NP	D	20026
@NP	Quantification of fluorescent signals of neurocan in the media and OEC groups	20029
@NP	Quantification	20029
@NP	fluorescent signals of neurocan in the media and OEC groups	20047
@NP	fluorescent signals	20047
@NP	neurocan in the media and OEC groups	20070
@NP	neurocan	20070
@NP	the media and OEC groups	20082
@NP	Vertical bars : SD .	20108
@NP	Vertical bars	20108
@NP	SD	20123
@NP	mRNA expression	20128
@NP	MMPs in cultured OECs The mRNA expressions of Mmp2 , Mmp3 and Mmp9	20147
@NP	MMPs	20147
@NP	OECs	20164
@NP	The mRNA expressions of Mmp2 , Mmp3 and Mmp9	20169
@NP	The mRNA expressions	20169
@NP	Mmp2 , Mmp3 and Mmp9	20193
@NP	OECs -LRB- Fig. 2A -RRB-	20239
@NP	OECs	20239
@NP	Fig. 2A	20245
@NP	No significant difference	20255
@NP	three independent OEC cultures in each mRNA expression	20302
@NP	three independent OEC cultures	20302
@NP	each mRNA expression	20336
@NP	Secretion of MMPs from cultured OECs The results of the gelatin zymography	20358
@NP	Secretion	20358
@NP	MMPs from cultured OECs The results of the gelatin zymography	20371
@NP	MMPs	20371
@NP	OECs	20390
@NP	The results of the gelatin zymography	20395
@NP	The results	20395
@NP	the gelatin zymography	20410
@NP	MMP-2 -LRB- 68 kD -RRB-	20448
@NP	MMP-2	20448
@NP	68 kD	20455
@NP	the OEC-CM	20479
@NP	MMP-9 -LRB- 92 kD -RRB-	20499
@NP	MMP-9	20499
@NP	92 kD	20506
@NP	Fig. 2B	20531
@NP	MMP-3	20541
@NP	the OEC-CM	20567
@NP	casein zymography -LRB- data not shown -RRB-	20581
@NP	casein zymography	20581
@NP	data not shown	20600
@NP	data	20600
@NP	Evaluation of	20617
@NP	Evaluation	20617
@NP	SCI	20639
@NP	HE	20646
@NP	the intact rat	20661
@NP	spinal cord , gray matter , which was stained strongly by hematoxylin and eosin	20676
@NP	spinal cord	20676
@NP	gray matter	20689
@NP	hematoxylin and eosin	20732
@NP	white matter , whose staining was faint ,	20759
@NP	white matter	20759
@NP	staining	20779
@NP	Fig. 3A	20829
@NP	the induced SCI/injured spinal cord	20842
@NP	the typical structure of gray matter and white matter	20879
@NP	the typical structure	20879
@NP	gray matter and white matter	20904
@NP	gray matter	20904
@NP	white matter	20920
@NP	the area of the lesion epicenter	20954
@NP	the area	20954
@NP	the lesion epicenter	20966
@NP	a large cavity across the T9-T10 spinal level	20988
@NP	a large cavity	20988
@NP	the T9-T10 spinal level	21010
@NP	eosinophilic cells	21050
@NP	the cavity -LRB- Fig. 3B -RRB-	21085
@NP	the cavity	21085
@NP	Fig. 3B	21097
@NP	There	21107
@NP	no tissue sections	21118
@NP	normal structure of spinal cord among the induced SCI animals	21153
@NP	normal structure	21153
@NP	spinal cord among the induced SCI animals	21173
@NP	spinal cord	21173
@NP	the induced SCI animals	21191
@NP	the injury	21232
@NP	the power	21251
@NP	250 kDyne spread at least 5 mm cranial and caudal from the point of impact	21264
@NP	250 kDyne spread at least 5 mm cranial	21264
@NP	250 kDyne spread	21264
@NP	at least 5 mm cranial	21281
@NP	caudal from the point of impact	21307
@NP	caudal	21307
@NP	the point of impact	21319
@NP	the point	21319
@NP	impact	21332
@NP	Expression	21340
@NP	MMP-2	21354
@NP	OECs	21363
@NP	injured spinal cord	21384
@NP	intact spinal cord	21407
@NP	the expression of MMP-2	21427
@NP	the expression	21427
@NP	MMP-2	21445
@NP	the area of gray matter -LRB- Fig. 4A-C -RRB-	21466
@NP	the area	21466
@NP	gray matter -LRB- Fig. 4A-C -RRB-	21478
@NP	gray matter	21478
@NP	Fig. 4A-C	21491
@NP	the media group	21506
@NP	the structure consisting of gray matter and white matter	21523
@NP	the structure	21523
@NP	gray matter and white matter	21551
@NP	gray matter	21551
@NP	white matter	21567
@NP	only a weak expression of MMP-2	21599
@NP	only a weak expression	21599
@NP	MMP-2	21625
@NP	Fig. 4D-F	21645
@NP	the OEC group	21660
@NP	MMP-2	21684
@NP	injured spinal cord	21719
@NP	the expression of MMP-2	21744
@NP	the expression	21744
@NP	MMP-2	21762
@NP	Hoechst 33342	21788
@NP	positive nuclei -LRB- Fig. 4G-I -RRB-	21803
@NP	positive nuclei	21803
@NP	Fig. 4G-I	21820
@NP	Fluorescent intensity of neurocan	21832
@NP	Fluorescent intensity	21832
@NP	neurocan	21857
@NP	the intact spinal cords , neurocan expression	21869
@NP	spinal cords , neurocan	21880
@NP	spinal cords	21880
@NP	neurocan	21894
@NP	gray matter	21935
@NP	faint or no expression	21948
@NP	white matter -LRB- Fig. 5A -RRB-	21987
@NP	white matter	21987
@NP	Fig. 5A	22001
@NP	the injured spinal cords	22014
@NP	neurocan	22040
@NP	the area of remaining tissue -LRB- Fig. 5B -RRB-	22073
@NP	the area	22073
@NP	remaining tissue -LRB- Fig. 5B -RRB-	22085
@NP	remaining tissue	22085
@NP	Fig. 5B	22103
@NP	The evaluation of immunofluorescent intensity	22113
@NP	The evaluation	22113
@NP	immunofluorescent intensity	22131
@NP	only the media group -LRB- B -RRB- and the OEC group	22181
@NP	the media group -LRB- B -RRB-	22186
@NP	the media group	22186
@NP	B	22203
@NP	the OEC group	22210
@NP	C	22225
@NP	the intact spinal cords	22236
@NP	a structure and staining pattern	22264
@NP	those of the injured spinal cord	22330
@NP	those	22330
@NP	the injured spinal cord	22339
@NP	The immunoreactivity of neurocan in the OEC group	22364
@NP	The immunoreactivity	22364
@NP	neurocan in the OEC group	22388
@NP	neurocan	22388
@NP	the OEC group	22400
@NP	that in the media group -LRB- Fig. 5B , C -RRB-	22430
@NP	that	22430
@NP	the media group -LRB- Fig. 5B , C -RRB-	22438
@NP	the media group	22438
@NP	Fig. 5B , C	22455
@NP	Fig. 5B	22455
@NP	C	22464
@NP	The quantification of immunoreactivity	22468
@NP	The quantification	22468
@NP	immunoreactivity	22490
@NP	a significant decrease of neurocan expression	22517
@NP	a significant decrease	22517
@NP	neurocan expression	22543
@NP	the OEC group	22566
@NP	MIVs	22581
@NP	38.48 ± 3.26	22587
@NP	the media group vs. 28.69 ± 1.10 in the OEC group , p 0 0.047 , Fig. 5D	22603
@NP	the media group	22603
@NP	28.69 ± 1.10 in the OEC group , p 0 0.047 , Fig. 5D	22623
@NP	1.10 in the OEC group	22631
@NP	1.10	22631
@NP	the OEC group	22639
@NP	p 0 0.047	22654
@NP	p	22654
@NP	0 0.047	22656
@NP	Fig. 5D	22665
@NP	Fig.	22665
@NP	5D	22670
@NP	Discussion The RT-PCR results	22676
@NP	Discussion	22676
@NP	The RT-PCR	22687
@NP	the cultured OECs	22718
@NP	the	22718
@NP	OECs	22731
@NP	mRNA of Mmp2 , Mmp3 and Mmp9	22746
@NP	mRNA	22746
@NP	Mmp2 , Mmp3 and Mmp9	22754
@NP	our knowledge	22778
@NP	this	22793
@NP	the first study reporting the mRNA expression of Mmp3 in cultured OECs	22801
@NP	the first study	22801
@NP	the mRNA expression of Mmp3	22827
@NP	the mRNA expression	22827
@NP	Mmp3	22850
@NP	OECs	22867
@NP	Our substrate zymography results	22873
@NP	the	22918
@NP	OECs	22931
@NP	MMP-2	22945
@NP	culture supernatants	22956
@NP	MMP-3 and -9	22986
@NP	MMP-3	22986
@NP	-9	22996
@NP	the OEC-CM	23020
@NP	These findings	23032
@NP	OECs	23060
@NP	MMP-2	23075
@NP	MMP-3 and -9	23102
@NP	MMP-3	23102
@NP	-9	23112
@NP	the mRNA expression of Mmp3 and Mmp9 in cultured OECs	23124
@NP	the mRNA expression	23124
@NP	Mmp3 and Mmp9 in cultured OECs	23147
@NP	Mmp3 and Mmp9	23147
@NP	OECs	23173
@NP	protein expression	23211
@NP	earlier studies	23240
@NP	MMP-9 secretion	23265
@NP	OECs	23284
@NP	their results	23290
@NP	a weaker expression of MMP-9 protein	23316
@NP	a weaker expression	23316
@NP	MMP-9 protein	23339
@NP	that of MMP-210,26	23365
@NP	that	23365
@NP	MMP-210,26	23373
@NP	the results of substrate zymography	23389
@NP	the results	23389
@NP	substrate zymography	23404
@NP	MMP-2	23440
@NP	the major MMP secreted by OECs	23450
@NP	the major MMP	23450
@NP	OECs	23476
@NP	we	23482
@NP	the relevance of MMP-2 secretion	23495
@NP	the relevance	23495
@NP	MMP-2 secretion	23512
@NP	OECs and the degradation of neurocan in a rat injured spinal cord model	23531
@NP	OECs	23531
@NP	the degradation of neurocan in a rat injured spinal cord model	23540
@NP	the degradation	23540
@NP	neurocan in a rat injured spinal cord model	23559
@NP	neurocan	23559
@NP	a rat injured spinal cord model	23571
@NP	a rat	23571
@NP	spinal cord model	23585
@NP	An intense immunofluorescent signal	23604
@NP	MMP-2 in the OEC group associated with Hoechst 33342-positive nuclei	23643
@NP	MMP-2	23643
@NP	the OEC group associated with Hoechst 33342-positive nuclei	23652
@NP	the OEC group	23652
@NP	Hoechst 33342-positive nuclei	23682
@NP	We	23726
@NP	this finding	23743
@NP	the transplanted OECs	23770
@NP	MMP-2 in the injured spinal cord	23801
@NP	MMP-2	23801
@NP	the injured spinal cord	23810
@NP	there	23844
@NP	a direct verification	23858
@NP	the transplanted OECs	23885
@NP	MMP-2	23916
@NP	there	23926
@NP	a possibility	23936
@NP	cells	23955
@NP	the transplanted OECs or parenchymal cells of spinal cord secreted MMP-2	23972
@NP	the transplanted OECs	23972
@NP	parenchymal cells of spinal cord secreted MMP-2	23997
@NP	parenchymal cells	23997
@NP	spinal cord secreted MMP-2	24018
@NP	spinal cord	24018
@NP	MMP-2	24039
@NP	our	24046
@NP	investigation	24059
@NP	the ability	24080
@NP	OECs to secrete MMP-2	24095
@NP	MMP-2	24111
@NP	an earlier study also suggested that OECs in vivo situation secrete MMP-210	24122
@NP	an earlier study	24122
@NP	OECs	24159
@NP	situation	24172
@NP	MMP-210	24190
@NP	The above-cited study by Pastrana et al.	24200
@NP	The above-cited study	24200
@NP	Pastrana et al.	24225
@NP	Pastrana	24225
@NP	et al.	24234
@NP	an immortalized cell line of OECs	24253
@NP	an	24253
@NP	cell line of OECs	24269
@NP	cell line	24269
@NP	OECs	24282
@NP	the ability to secrete MMP-2 in injured spinal cord26	24292
@NP	MMP-2	24315
@NP	injured spinal cord26	24324
@NP	We	24348
@NP	the intense expression of MMP-2 associated with Hoechst 33342-positive nuclei	24375
@NP	the intense expression	24375
@NP	MMP-2 associated with Hoechst 33342-positive nuclei	24401
@NP	MMP-2	24401
@NP	Hoechst 33342-positive nuclei	24423
@NP	the secretion of MMP-2	24463
@NP	the secretion	24463
@NP	MMP-2	24480
@NP	transplanted OECs	24491
@NP	addition	24513
@NP	the immunofluorescent signal of neurocan	24523
@NP	the immunofluorescent signal	24523
@NP	neurocan	24555
@NP	the present study 's OEC group	24595
@NP	the present study 's	24595
@NP	we	24630
@NP	this result	24646
@NP	neurocan	24673
@NP	the transplantation of OECs	24699
@NP	the transplantation	24699
@NP	OECs	24722
@NP	Neurocan	24728
@NP	reactive astrocytes in injured spinal cord1	24774
@NP	reactive astrocytes	24774
@NP	injured spinal cord1	24797
@NP	it	24829
@NP	cells	24867
@NP	neurocan	24883
@NP	our immunofluorescence results	24895
@NP	the transplanted OECs	24945
@NP	neurocan	24983
@NP	We	24993
@NP	the expression of neurocan	25011
@NP	the expression	25011
@NP	neurocan	25029
@NP	the transplanted OECs	25074
@NP	neurocan	25106
@NP	a significant level	25118
@NP	there	25148
@NP	a possibility	25164
@NP	the transplanted OECs	25183
@NP	neurocan	25215
@NP	an insignificant level	25227
@NP	we	25251
@NP	the significant decrease of neurocan by OEC transplantation	25270
@NP	the significant decrease	25270
@NP	neurocan by OEC transplantation	25298
@NP	neurocan	25298
@NP	OEC transplantation	25310
@NP	a larger sense	25334
@NP	the possibility of OECs expressing neurocan at an insignificant level	25354
@NP	the possibility	25354
@NP	OECs expressing neurocan at an insignificant level	25373
@NP	OECs	25373
@NP	neurocan	25389
@NP	an insignificant level	25401
@NP	our findings	25441
@NP	OECs	25459
@NP	MMP-2 in injured spinal cord	25473
@NP	MMP-2	25473
@NP	injured spinal cord	25482
@NP	neurocan	25511
@NP	the transplantation of OECs	25537
@NP	the transplantation	25537
@NP	OECs	25560
@NP	us	25569
@NP	this decrease in neurocan	25589
@NP	this decrease	25589
@NP	neurocan	25606
@NP	the degradation of neurocan	25635
@NP	the degradation	25635
@NP	neurocan	25654
@NP	MMP-2 secreted from transplanted OECs	25666
@NP	MMP-2	25666
@NP	transplanted OECs	25686
@NP	this study	25714
@NP	several limitations	25729
@NP	the lack	25760
@NP	an investigation	25772
@NP	the effect	25792
@NP	OECs	25806
@NP	other species of CSPGs	25814
@NP	other species	25814
@NP	CSPGs	25831
@NP	the lack	25841
@NP	an evaluation	25853
@NP	the effects of OECs on axonal regeneration or locomotor function	25870
@NP	the effects	25870
@NP	OECs on axonal regeneration or locomotor function	25885
@NP	OECs	25885
@NP	axonal regeneration or locomotor function	25893
@NP	our results	25936
@NP	a new property of OECs in vitro and in injured spinal cord	25958
@NP	a new property	25958
@NP	OECs in vitro and in injured spinal cord	25976
@NP	OECs	25976
@NP	injured spinal cord	25997
@NP	Further investigation	26018
@NP	the properties of OECs	26073
@NP	the properties	26073
@NP	OECs	26091
@NP	OEC transplantation	26113
@NP	a treatment for severe SCI	26136
@NP	a treatment	26136
@NP	severe SCI	26152
@VP	is not fully understood	401
@VP	fully understood	408
@VP	has been suggested	480
@VP	been suggested	484
@VP	suggested	489
@VP	evaluated the expression of MMPs in OECs in vitro	503
@VP	using a rat SCI model	627
@VP	is one of the axon-inhibitory chondroitin sulfate proteoglycans	703
@VP	using SCI model rats	768
@VP	in vitro results showed that MMP-2 was the dominant MMP expressed by OECs	794
@VP	was the dominant MMP expressed by OECs	829
@VP	expressed by OECs	850
@VP	revealed that transplanted OECs secreted MMP-2 in injured spinal cord	889
@VP	secreted MMP-2 in injured spinal cord	921
@VP	was significantly decreased by the transplantation of OECs	995
@VP	decreased by the transplantation of OECs	1013
@VP	transplanted into injured spinal cord degraded neurocan by secreting MMP-2	1087
@VP	degraded neurocan by secreting MMP-2	1125
@VP	secreting MMP-2	1146
@VP	is relatively common in dogs9 ,11,15	1266
@VP	suffer from irreversible quadriplegia or paraplegia and incontinence	1329
@VP	have been performed	1449
@VP	been performed	1454
@VP	performed	1459
@VP	has not been established	1493
@VP	been established	1501
@VP	established	1506
@VP	has been actively investigated	1548
@VP	been actively investigated	1552
@VP	actively investigated	1557
@VP	have been presented	1602
@VP	been presented	1607
@VP	presented	1612
@VP	induced pluripotent stem cells6 ,23	1773
@VP	been described as a promising candidate for cell transplantation therapy in SCI	1852
@VP	described as a promising candidate for cell transplantation therapy in SCI	1857
@VP	are specific glial cells in the olfactory system	1938
@VP	have the notable ability to support axonal regeneration	1997
@VP	to support axonal regeneration	2022
@VP	support axonal regeneration	2025
@VP	was achieved with OEC transplantation in SCI models2 ,7,13,17,19,25,27,28	2108
@VP	achieved with OEC transplantation in SCI models2 ,7,13,17,19,25,27,28	2112
@VP	centered on the evaluation of functional recovery	2214
@VP	underlying the functional recovery achieved with OEC transplantation	2284
@VP	achieved with OEC transplantation	2319
@VP	have not been investigated in detail	2353
@VP	been investigated in detail	2362
@VP	investigated in detail	2367
@VP	secreting neurotrophic factor4 -RRB-	2472
@VP	demyelinated axons2 ,7,18,19 -RRB-	2522
@VP	survived injury27	2585
@VP	has presented a definite answer to this question	2617
@VP	presented a definite answer to this question	2621
@VP	been reported to be due to chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	2698
@VP	reported to be due to chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	2703
@VP	to be due to chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	2712
@VP	be due to chondroitin sulfate proteoglycans -LRB- CSPGs -RRB-	2715
@VP	inhibiting axonal regeneration in the injured spinal cord3 ,16,29 -RRB-	2814
@VP	include several species	2887
@VP	reported for brevican , versican , neurocan , NG2 , and phosphacan8 ,12,20 -RRB-	2969
@VP	was recently suggested to be the major inhibitory CSPG in SCI1	3073
@VP	suggested to be the major inhibitory CSPG in SCI1	3086
@VP	to be the major inhibitory CSPG in SCI1	3096
@VP	be the major inhibitory CSPG in SCI1	3099
@VP	promoted functional recovery in rodent SCI models3 ,30	3185
@VP	was suggested in 2006 by Pastrana et al. 26 -RRB-	3292
@VP	suggested in 2006 by Pastrana et al. 26 -RRB-	3296
@VP	cultured OECs	3424
@VP	promoted the axonal regeneration of retinal neurons in vitro26 -RRB-	3466
@VP	are a family of endopeptidases that contain Zn2 ＋ in the catalytic domain	3536
@VP	contain Zn2 ＋ in the catalytic domain	3572
@VP	is the modulation of the extracellular matrix -LRB- ECM -RRB- 22 -RRB-	3647
@VP	been reported to have the ability to degrade CSPGs , which are a type of ECM21	3746
@VP	reported to have the ability to degrade CSPGs , which are a type of ECM21	3751
@VP	to have the ability to degrade CSPGs , which are a type of ECM21	3760
@VP	have the ability to degrade CSPGs , which are a type of ECM21	3763
@VP	to degrade CSPGs , which are a type of ECM21	3780
@VP	degrade CSPGs , which are a type of ECM21	3783
@VP	are a type of ECM21	3804
@VP	presented a detailed report of MMP expression in OECs10 -RRB-	3839
@VP	to degrade all five species of CSPGs that inhibit axonal regeneration	3947
@VP	degrade all five species of CSPGs that inhibit axonal regeneration	3950
@VP	inhibit axonal regeneration	3989
@VP	has not been investigated in OECs , to our knowledge	4017
@VP	been investigated in OECs , to our knowledge	4025
@VP	investigated in OECs , to our knowledge	4030
@VP	has also not been examined in detail	4193
@VP	been examined in detail	4206
@VP	examined in detail	4211
@VP	cultured rat OECs	4324
@VP	determined which MMPs are dominantly expressed by cultured OECs	4350
@VP	are dominantly expressed by cultured OECs	4372
@VP	expressed by cultured OECs	4387
@VP	cultured OECs	4400
@VP	cultured OECs , using OEC transplantation into SCI model animals	4508
@VP	using OEC transplantation into SCI model animals	4523
@VP	were used to culture OECs	4660
@VP	used to culture OECs	4665
@VP	were used for the induced SCI model	4718
@VP	used for the induced SCI model	4723
@VP	was used for the following evaluations and transplantation	5222
@VP	used for the following evaluations and transplantation	5226
@VP	were used for reverse transcription-polymerase chain reaction -LRB- RT-PCR -RRB-	5309
@VP	used for reverse transcription-polymerase chain reaction -LRB- RT-PCR -RRB-	5314
@VP	were used for substrate zymography	5396
@VP	used for substrate zymography	5401
@VP	were used for transplantation in SCI model rats	5447
@VP	used for transplantation in SCI model rats	5452
@VP	was used for the evaluation of the purity of the cultured OECs	5535
@VP	used for the evaluation of the purity of the cultured OECs	5539
@VP	cultured OECs	5584
@VP	were sacrificed at a time	5609
@VP	sacrificed at a time	5614
@VP	were used to establish one culture	5664
@VP	used to establish one culture	5669
@VP	to establish one culture	5674
@VP	establish one culture	5677
@VP	were based on those used in earlier studies , with minor modifications24 ,31	5744
@VP	based on those used in earlier studies , with minor modifications24 ,31	5749
@VP	ensuring the loss of eyelid reflex	5938
@VP	were decapitated	5986
@VP	decapitated	5991
@VP	collected aseptically	6062
@VP	were stripped off	6213
@VP	stripped off	6218
@VP	was dissected	6270
@VP	dissected	6274
@VP	chopped with a scalpel blade	6300
@VP	was added	6494
@VP	added	6498
@VP	was incubated at 37 °C for another 15 min	6521
@VP	incubated at 37 °C for another 15 min	6525
@VP	as a defined medium -LRB- DM -LRB- + -RRB- -RRB- and spun at 220 × g for 5 min	6768
@VP	as a defined medium -LRB- DM -LRB- + -RRB- -RRB-	6768
@VP	spun at 220 × g for 5 min	6801
@VP	containing bovine serum albumin -LRB- 0.3 mg/ml ; Sigma -RRB-	6969
@VP	triturated 10 times using a 5-ml glass pipette	7025
@VP	using a 5-ml glass pipette	7045
@VP	gauge needles with a 1-ml syringe , respectively	7112
@VP	were then washed with 10 ml of DM -LRB- + -RRB- and spun at 220 × g for 5 min	7173
@VP	washed with 10 ml of DM -LRB- + -RRB- and spun at 220 × g for 5 min	7183
@VP	and spun at 220 × g for 5 min	7211
@VP	spun at 220 × g for 5 min	7215
@VP	were plated on 90-mm-dia	7427
@VP	plated on 90-mm-dia	7432
@VP	GM -LRB- + -RRB- for 24	7494
@VP	containing floating cells	7557
@VP	was transferred to other dishes and incubated for 48 hr	7583
@VP	transferred to other dishes and incubated for 48 hr	7587
@VP	transferred to other dishes	7587
@VP	incubated for 48 hr	7619
@VP	containing floating cells	7679
@VP	was added to each dish	7771
@VP	added to each dish	7775
@VP	were maintained at 37 °C in 5 % CO2	7804
@VP	maintained at 37 °C in 5 % CO2	7809
@VP	was replaced with 5 ml of GM -LRB- + -RRB- at 6 days in vitro -LRB- DIV -RRB-	7867
@VP	replaced with 5 ml of GM -LRB- + -RRB- at 6 days in vitro -LRB- DIV -RRB-	7871
@VP	of GM -LRB- + -RRB- at 6 days in vitro	7890
@VP	GM -LRB- + -RRB- at 6	7893
@VP	was renewed every 2-3 days until the culture reached confluence	7957
@VP	renewed every 2-3 days until the culture reached confluence	7961
@VP	reached confluence	8002
@VP	reaching confluence	8028
@VP	cultured OECs	8168
@VP	ensured a purity of ＞ 95 % -LRB- data not shown -RRB-	8433
@VP	not shown	8465
@VP	used RT-PCR to analyze the mRNA expressions of MMPs in the OECs	8488
@VP	to analyze the mRNA expressions of MMPs in the OECs	8500
@VP	analyze the mRNA expressions of MMPs in the OECs	8503
@VP	was also subjected to RT-PCR	8636
@VP	subjected to RT-PCR	8645
@VP	was digested by DNase I -LRB- Qiagen -RRB-	8828
@VP	digested by DNase I -LRB- Qiagen -RRB-	8832
@VP	diluted 10-fold	9014
@VP	sets for Gapdh given in a previous report were used14	9250
@VP	were used14	9292
@VP	was used	9342
@VP	used	9346
@VP	started at 94 °C for 2 min	9352
@VP	repeating 35 cycles of 94 °C for 1 min , 60 °C for 1 min , and 72 °C for 2 min	9379
@VP	were visualized using a Printgraph ® device -LRB- Atto , Tokyo -RRB-	9535
@VP	visualized using a Printgraph ® device -LRB- Atto , Tokyo -RRB-	9540
@VP	using a Printgraph ® device -LRB- Atto , Tokyo -RRB-	9551
@VP	was performed to detect the secretion of MMP-2 , -3 , and -9 from OECs	9636
@VP	performed to detect the secretion of MMP-2 , -3 , and -9 from OECs	9640
@VP	to detect the secretion of MMP-2 , -3 , and -9 from OECs	9650
@VP	detect the secretion of MMP-2 , -3 , and -9 from OECs	9653
@VP	were passaged onto a poly-L-lysine-coated 60-mm-dia	9719
@VP	passaged onto a poly-L-lysine-coated 60-mm-dia	9724
@VP	∧ 6 cells/dish in 6 ml of GM -LRB- + -RRB-	9786
@VP	collected as OEC-conditioned media -LRB- OEC-CM -RRB-	10021
@VP	centrifuged at 4 °C , 1000 × g for 10 min to remove floating cells	10069
@VP	to remove floating cells	10109
@VP	remove floating cells	10112
@VP	was dissolved in non-reducing	10354
@VP	dissolved in non-reducing	10358
@VP	containing 2.5 % t-octylphenoxypolyethoxyethanol -LRB- Triton-X ; Sigma -RRB-	10655
@VP	containing 100 mM Tris-HCl -LRB- pH 7.5 -RRB- , 5 μM ZnCl2 , and 5 mM CaCl2	10855
@VP	stained with 0.1 % Coomassie Brilliant Blue R-250	10952
@VP	destained in a solution of formic acid/methanol/water -LRB- 1 : 30 : 70 -RRB-	11005
@VP	appeared as clear bands against a dark background	11095
@VP	used as a positive control for gelatin zymography	11430
@VP	used as a technical control	11484
@VP	was established from human cells	11626
@VP	established from human cells	11630
@VP	were scanned in a digital scanner	11669
@VP	scanned in a digital scanner	11674
@VP	were converted to gray-scale using Adobe Photoshop 6.0	11727
@VP	converted to gray-scale using Adobe Photoshop 6.0	11732
@VP	using Adobe Photoshop 6.0	11756
@VP	were anesthetized with an i.p. injection of pentobarbital -LRB- 50 mg/kg -RRB-	11836
@VP	was performed at the T10 vertebral level -LRB- Fig. 1A -RRB-	11931
@VP	performed at the T10 vertebral level -LRB- Fig. 1A -RRB-	11935
@VP	used to make a severe -LRB- 250 kdyn ; 1dyn ＝ 10 ∧ -5 N -RRB- contusion injury1	12066
@VP	to make a severe -LRB- 250 kdyn ; 1dyn ＝ 10 ∧ -5 N -RRB- contusion injury1	12071
@VP	make a severe -LRB- 250 kdyn ; 1dyn ＝ 10 ∧ -5 N -RRB- contusion injury1	12074
@VP	were sutured	12171
@VP	sutured	12176
@VP	was closed	12201
@VP	closed	12205
@VP	were manually expressed twice a day until a bladder reflex was restored	12352
@VP	expressed twice a day until a bladder reflex was restored	12366
@VP	was restored	12411
@VP	restored	12415
@VP	was performed at 14-15 dpi	12470
@VP	performed at 14-15 dpi	12474
@VP	received fluorescent labeling as described5	12529
@VP	DM -LRB- + -RRB- at a density of 5 × 104 cells/μl	12671
@VP	were injected with OEC suspension -LRB- = the OEC group -RRB-	12733
@VP	injected with OEC suspension -LRB- = the OEC group -RRB-	12738
@VP	were anesthetized with pentobarbital -LRB- 50 mg/kg , i.p. -RRB-	12892
@VP	was carefully exposed	12984
@VP	were decided using a microinjector -LRB- IMS-3 ; Narishige -RRB-	13202
@VP	decided using a microinjector -LRB- IMS-3 ; Narishige -RRB-	13207
@VP	using a microinjector -LRB- IMS-3 ; Narishige -RRB-	13215
@VP	running on the midline of the spinal cord	13495
@VP	performed at the lesion epicenter and 1 mm cranial and caudal from the epicenter	13542
@VP	were made -LRB- Fig. 1B -RRB-	13656
@VP	made -LRB- Fig. 1B -RRB-	13661
@VP	To avoid reflux of the suspension from the injection site	13795
@VP	avoid reflux of the suspension from the injection site	13798
@VP	was taken for each injection	13860
@VP	taken for each injection	13864
@VP	was left in place for another 1 min after the injection was completed	13905
@VP	left in place for another 1 min after the injection was completed	13909
@VP	was completed	13961
@VP	completed	13965
@VP	were closed in the same manner as that used for the preparation of injury	14016
@VP	closed in the same manner as that used for the preparation of injury	14021
@VP	used for the preparation of injury	14055
@VP	were allowed to recover in warmed cages overnight	14107
@VP	allowed to recover in warmed cages overnight	14112
@VP	to recover in warmed cages overnight	14120
@VP	recover in warmed cages overnight	14123
@VP	were performed in the same manner as that used for the preparation of injury	14213
@VP	performed in the same manner as that used for the preparation of injury	14218
@VP	used for the preparation of injury	14255
@VP	were sacrificed at 7-8 days after transplantation -LRB- 21-22 dpi -RRB-	14343
@VP	sacrificed at 7-8 days after transplantation -LRB- 21-22 dpi -RRB-	14348
@VP	were obtained	14434
@VP	obtained	14439
@VP	was also sacrificed to obtain intact spinal cord tissue	14479
@VP	sacrificed to obtain intact spinal cord tissue	14488
@VP	to obtain intact spinal cord tissue	14499
@VP	obtain intact spinal cord tissue	14502
@VP	perfused with 4 % paraformaldehyde-phosphatebuffered saline -LRB- PFA-PBS -RRB-	14627
@VP	was dissected and immediately placed on ice-cold PBS	14750
@VP	dissected and immediately placed on ice-cold PBS	14754
@VP	dissected	14754
@VP	immediately placed on ice-cold PBS	14768
@VP	were then stripped off	14817
@VP	stripped off	14827
@VP	were removed under stereomicroscopic observation	14861
@VP	removed under stereomicroscopic observation	14866
@VP	trimming	14917
@VP	were further fixed in 4 % PFA-PBS at 4 °C overnight	14939
@VP	fixed in 4 % PFA-PBS at 4 °C overnight	14952
@VP	containing 20 % -LRB- w/v -RRB- sucrose at 4 °C for more than 6 hr	15051
@VP	was performed in PBS solution containing 30 % -LRB- w/v -RRB- sucrose for 48 hr	15129
@VP	performed in PBS solution containing 30 % -LRB- w/v -RRB- sucrose for 48 hr	15133
@VP	containing 30 % -LRB- w/v -RRB- sucrose for 48 hr	15159
@VP	centered on the lesion epicenter	15241
@VP	was cut with a scalpel blade	15274
@VP	cut with a scalpel blade	15278
@VP	frozen rapidly by liquid nitrogen	15394
@VP	to evaluate the degree of injury by the power of 250 kDyne	15829
@VP	evaluate the degree of injury by the power of 250 kDyne	15832
@VP	diluted in TBS-T for 1 hr at room temperature	16123
@VP	washed with TBS-T three times for 5 min each time , and incubated with 1	16415
@VP	washed with TBS-T three times for 5 min each time	16415
@VP	incubated with 1	16470
@VP	washed with TBS-T three times for 5 min each time	16698
@VP	used laser scanning confocal microscopy	16985
@VP	analyzing the fluorescent signal intensity of neurocan	17070
@VP	was used for the observation of MMP-2	17285
@VP	used for the observation of MMP-2	17289
@VP	was used for neurocan , with the camera gain	17349
@VP	used for neurocan , with the camera gain	17353
@VP	offset set to fixed values for all samples	17397
@VP	set to fixed values for all samples	17404
@VP	was defined as the counterpart site	17701
@VP	defined as the counterpart site	17705
@VP	to analyze neurocan degradation from the digital images was as described1 -RRB-	17754
@VP	analyze neurocan degradation from the digital images was as described1 -RRB-	17757
@VP	was	17810
@VP	stained with Cy3	17875
@VP	were converted to gray-scale	17892
@VP	converted to gray-scale	17897
@VP	was calculated from the histogram of the signal intensity using Image-J software	17971
@VP	calculated from the histogram of the signal intensity using Image-J software	17975
@VP	using Image-J software	18029
@VP	are expressed as means ± SD	18087
@VP	expressed as means ± SD	18091
@VP	± SD	18110
@VP	to compare the MIVs of neurocan expression in the media and OEC groups	18163
@VP	compare the MIVs of neurocan expression in the media and OEC groups	18166
@VP	were considered significant	18255
@VP	considered significant	18260
@VP	to analyze the mRNA expressions of MMPsb -RRB- in OECsc -RRB-	18332
@VP	analyze the mRNA expressions of MMPsb -RRB- in OECsc -RRB-	18335
@VP	Dashed lines : Sampling point of sections	18627
@VP	expressed the mRNA of Mmp2 , Mmp3 and Mmp9 and secreted MMP-2 protein in vitro	18683
@VP	expressed the mRNA of Mmp2 , Mmp3 and Mmp9	18683
@VP	secreted MMP-2 protein in vitro	18729
@VP	A : The mRNA expressions of Mmp2 , Mmp3 and Mmp9 in OECs in vitro	18762
@VP	conditioned media -LRB- OEC-CM -RRB-	19003
@VP	conditioned media -LRB- mFB-CM -RRB-	19149
@VP	conditioned media -LRB- HT-1080-CM -RRB-	19193
@VP	was used as a molecular weight control of rat MMP-2 and -9	19232
@VP	used as a molecular weight control of rat MMP-2 and -9	19236
@VP	was used as an experimental control	19303
@VP	used as an experimental control	19307
@VP	= 1 mm	19548
@VP	= 20 μm	19743
@VP	= 200 μm	20016
@VP	cultured OECs The mRNA expressions of Mmp2 , Mmp3 and Mmp9	20155
@VP	were observed in cultured OECs -LRB- Fig. 2A -RRB-	20213
@VP	observed in cultured OECs -LRB- Fig. 2A -RRB-	20218
@VP	cultured OECs -LRB- Fig. 2A -RRB-	20230
@VP	was observed between three independent OEC cultures in each mRNA expression	20281
@VP	observed between three independent OEC cultures in each mRNA expression	20285
@VP	cultured OECs The results of the gelatin zymography	20381
@VP	was not detected -LRB- Fig. 2B -RRB-	20513
@VP	detected -LRB- Fig. 2B -RRB-	20521
@VP	was not detected in the OEC-CM by casein zymography -LRB- data not shown -RRB-	20547
@VP	detected in the OEC-CM by casein zymography -LRB- data not shown -RRB-	20555
@VP	not shown	20605
@VP	was stained strongly by hematoxylin and eosin	20708
@VP	stained strongly by hematoxylin and eosin	20712
@VP	was faint	20788
@VP	were clearly distinguishable -LRB- Fig. 3A -RRB-	20799
@VP	was not observed	20933
@VP	observed	20941
@VP	was formed	21034
@VP	formed	21038
@VP	appeared around the cavity -LRB- Fig. 3B -RRB-	21069
@VP	was limited in the area of gray matter -LRB- Fig. 4A-C -RRB-	21451
@VP	limited in the area of gray matter -LRB- Fig. 4A-C -RRB-	21455
@VP	consisting of gray matter and white matter	21537
@VP	was destroyed	21580
@VP	destroyed	21584
@VP	was observed -LRB- Fig. 4D-F -RRB-	21631
@VP	observed -LRB- Fig. 4D-F -RRB-	21635
@VP	was intensively expressed in injured spinal cord	21690
@VP	expressed in injured spinal cord	21706
@VP	was associated with Hoechst 33342 - positive nuclei -LRB- Fig. 4G-I -RRB-	21768
@VP	associated with Hoechst 33342 - positive nuclei -LRB- Fig. 4G-I -RRB-	21772
@VP	was observed only in gray matter	21914
@VP	observed only in gray matter	21918
@VP	was observed in white matter -LRB- Fig. 5A -RRB-	21971
@VP	observed in white matter -LRB- Fig. 5A -RRB-	21975
@VP	was expressed wholly in the area of remaining tissue -LRB- Fig. 5B -RRB-	22049
@VP	expressed wholly in the area of remaining tissue -LRB- Fig. 5B -RRB-	22053
@VP	were clearly different from those of the injured spinal cord	22302
@VP	was weaker than that in the media group -LRB- Fig. 5B , C -RRB-	22414
@VP	results	22698
@VP	showed that the cultured OECs expressed mRNA of Mmp2 , Mmp3 and Mmp9	22706
@VP	cultured OECs	22722
@VP	expressed mRNA of Mmp2 , Mmp3 and Mmp9	22736
@VP	is the first study reporting the mRNA expression of Mmp3 in cultured OECs	22798
@VP	reporting the mRNA expression of Mmp3 in cultured OECs	22817
@VP	cultured OECs	22858
@VP	were not detected in the OEC-CM	22999
@VP	detected in the OEC-CM	23008
@VP	expressed MMP-2 more abundantly than MMP-3 and -9	23065
@VP	cultured OECs	23164
@VP	was not high enough to appear as protein expression	23178
@VP	to appear as protein expression	23198
@VP	appear as protein expression	23201
@VP	reported MMP-9 secretion by OECs	23256
@VP	showed a weaker expression of MMP-9 protein compared to that of MMP-210,26	23309
@VP	suggested that MMP-2 was the major MMP secreted by OECs	23425
@VP	was the major MMP secreted by OECs	23446
@VP	secreted by OECs	23464
@VP	injured spinal cord model	23577
@VP	associated with Hoechst 33342-positive nuclei	23666
@VP	was observed	23712
@VP	observed	23716
@VP	suggests that the transplanted OECs secreted MMP-2 in the injured spinal cord	23756
@VP	secreted MMP-2 in the injured spinal cord	23792
@VP	was not a direct verification that the transplanted OECs secreted MMP-2	23850
@VP	secreted MMP-2	23907
@VP	secreted MMP-2	24030
@VP	to secrete MMP-2	24100
@VP	secrete MMP-2	24103
@VP	also suggested that OECs in vivo situation secrete MMP-210	24139
@VP	in vivo situation secrete MMP-210	24164
@VP	immortalized cell line of OECs	24256
@VP	kept the ability to secrete MMP-2 in injured spinal cord26	24287
@VP	to secrete MMP-2 in injured spinal cord26	24304
@VP	secrete MMP-2 in injured spinal cord26	24307
@VP	associated with Hoechst 33342-positive nuclei	24407
@VP	indicates the secretion of MMP-2 from transplanted OECs	24453
@VP	was significantly decreased in the present study 's OEC group	24564
@VP	decreased in the present study 's OEC group	24582
@VP	indicates that neurocan was decreased by the transplantation of OECs	24658
@VP	was decreased by the transplantation of OECs	24682
@VP	decreased by the transplantation of OECs	24686
@VP	has been reported to be expressed by reactive astrocytes in injured spinal cord1	24737
@VP	been reported to be expressed by reactive astrocytes in injured spinal cord1	24741
@VP	reported to be expressed by reactive astrocytes in injured spinal cord1	24746
@VP	to be expressed by reactive astrocytes in injured spinal cord1	24755
@VP	be expressed by reactive astrocytes in injured spinal cord1	24758
@VP	expressed by reactive astrocytes in injured spinal cord1	24761
@VP	to distinguish which cells expressed neurocan in our immunofluorescence results	24846
@VP	distinguish which cells expressed neurocan in our immunofluorescence results	24849
@VP	expressed neurocan in our immunofluorescence results	24873
@VP	to verify that the transplanted OECs did not express neurocan	24930
@VP	verify that the transplanted OECs did not express neurocan	24933
@VP	did not express neurocan	24967
@VP	express neurocan	24975
@VP	expressed neurocan at a significant level	25096
@VP	expressed neurocan at an insignificant level	25205
@VP	expressing neurocan at an insignificant level	25378
@VP	Taken together	25425
@VP	secreted MMP-2 in injured spinal cord	25464
@VP	was decreased by the transplantation of OECs	25520
@VP	decreased by the transplantation of OECs	25524
@VP	secreted from transplanted OECs	25672
@VP	clarified a new property of OECs in vitro and in injured spinal cord	25948
@VP	to fully understand the properties of OECs	26053
@VP	understand the properties of OECs	26062
@VP	to establish OEC transplantation as a treatment for severe SCI	26100
@VP	establish OEC transplantation as a treatment for severe SCI	26103
